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Abstract
Activation of cannabinoid CB1 receptors (CB1R) by delta9-tetrahydrocannabinol (THC) pro-
duces a variety of negative effects with major consequences in cannabis users that consti-
tute important drawbacks for the use of cannabinoids as therapeutic agents. For this
reason, there is a tremendous medical interest in harnessing the beneficial effects of THC.
Behavioral studies carried out in mice lacking 5-HT2A receptors (5-HT2AR) revealed a
remarkable 5-HT2AR-dependent dissociation in the beneficial antinociceptive effects of
THC and its detrimental amnesic properties. We found that specific effects of THC such as
memory deficits, anxiolytic-like effects, and social interaction are under the control of 5-
HT2AR, but its acute hypolocomotor, hypothermic, anxiogenic, and antinociceptive effects
are not. In biochemical studies, we show that CB1R and 5-HT2AR form heteromers that are
expressed and functionally active in specific brain regions involved in memory impairment.
Remarkably, our functional data shows that costimulation of both receptors by agonists
reduces cell signaling, antagonist binding to one receptor blocks signaling of the interacting
receptor, and heteromer formation leads to a switch in G-protein coupling for 5-HT2AR from
Gq to Gi proteins. Synthetic peptides with the sequence of transmembrane helices 5 and 6
of CB1R, fused to a cell-penetrating peptide, were able to disrupt receptor heteromerization
in vivo, leading to a selective abrogation of memory impairments caused by exposure to
THC. These data reveal a novel molecular mechanism for the functional interaction
between CB1R and 5-HT2AR mediating cognitive impairment. CB1R-5-HT2AR heteromers
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are thus good targets to dissociate the cognitive deficits induced by THC from its beneficial
antinociceptive properties.
Author Summary
Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound of marijuana,
induces numerous undesirable effects, including memory impairments, anxiety, and
dependence. Conversely, THC also has potentially therapeutic effects, including analgesia,
muscle relaxation, and neuroprotection. However, the mechanisms that dissociate these
responses are still not known. Using mice lacking the serotonin receptor 5-HT2A, we
revealed that the analgesic and amnesic effects of THC are independent of each other:
while amnesia induced by THC disappears in the mutant mice, THC can still promote
analgesia in these animals. In subsequent molecular studies, we showed that in specific
brain regions involved in memory formation, the receptors for THC and the 5-HT2A
receptors work together by physically interacting with each other. Experimentally interfer-
ing with this interaction prevented the memory deficits induced by THC, but not its anal-
gesic properties. Our results highlight a novel mechanism by which the beneficial
analgesic properties of THC can be dissociated from its cognitive side effects.
Introduction
The administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive compound
in Cannabis sativa, induces numerous behavioral responses related to undesirable effects,
including memory impairments [1,2], anxiogenic effects [3], and dependence [4,5]. However,
other effects of THC are associated with potential therapeutic applications, including analgesia
[6] and anxiolytic-like and neuroprotective effects [3,5,7]. One major challenge in the field of
cannabinoids is to identify new mechanisms that could be used to dissociate these responses in
order to improve the benefit-risk ratio of cannabinoid agonists. Cannabinoid behavioral effects
are mainly due to the activation of central CB1 cannabinoid receptors (CB1R) [5]. CB1R activa-
tion has been shown to modulate a wide range of neurotransmitters in the brain, including glu-
tamate, γ-aminobutyric acid (GABA), opioids, dopamine, and serotonin, which could
participate in THC pharmacological responses [4,5]. Recent evidence shows that THC and
other cannabinoids modulate behaviors typically mediated by serotonin 2A receptors’
(5-HT2AR) activation [8–10]. In addition, mice lacking CB1R exhibit a dysregulation of seroto-
nergic activity in the prefrontal cortex [11] and reduced head twitches induced by the 5-HT2AR
agonist, (±)-1-(2,5-dimethoixy-4-odophenyl)-2-aminopropane (DOI) [12]. Reciprocally, the
activation of 5-HT2AR expressed in cells stimulates the formation and release of the endocan-
nabinoid, 2-arachidonoylglycerol (2-AG) [13,14]. Both 5-HT2AR and CB1R are expressed in
brain structures involved in regulating emotions, learning, and memory, including the amyg-
dala, cerebral cortex, and hippocampus [15–17]. CB1Rs are highly expressed presynaptically in
the prefrontal cortex [18–20] and in the hippocampus [21], where moderate expression of
5-HT2AR has also been observed [16,22,23]. In the rat striatum, CB1R expression has been
detected in dendrites of spiny- and aspiny-type somata [24], coinciding with the observed den-
dritic expression of 5-HT2AR in this area [25–27]. Moreover, 5-HT2AR is involved in different
psychotic manifestations [28,29], while adolescent consumption of cannabis enhances the inci-
dence of psychotic symptoms [30,31]. Collectively, these data suggest possible bidirectional
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interactions between CB1R- and 5-HT2AR-mediated pharmacological responses, although a
cellular mechanism for this cross talk has yet to be discovered. Here we sought to understand
at what level the interactions of these two systems occur. Using a variety of in vivo and in vitro
assays, we reveal a new molecular mechanism by which the cognitive deficits of THC can be
dissociated from its beneficial antinociceptive properties.
Using transgenic mice lacking 5-HT2AR, we found that these two receptors do indeed inter-
act in heteromeric complexes. Importantly, these heteromers are specifically required for the
amnesic, anxiolytic, and social interaction effects caused by THC, but not for other pharmaco-
logical responses, such as antinociception and hypolocomotion. Interestingly, the activation of
this complex in cells expressing both receptors resulted in a reduction of intracellular signaling
through adenylate cyclase, arrestin recruitment, and the extracellular signal-regulated kinase
(ERK) 1/2 and protein kinase B (Akt) pathways, confirming altered downstream signaling. The
formation of this receptor complex in the brain and its selective involvement in THC-induced
memory and anxiety-like responses was further evidenced by the use of transmembrane helix
(TM) 5 and TM 6 interference peptides in vivo. Hence, the disruption of the CB1R-5-HT2AR
heteromer by intracerebroventricular (ICV) infusion of these peptides abolished the memory
deficits induced by THC and its anxiolytic-like effects, but not its antinociceptive properties.
Our findings reveal a new molecular mechanism by which the cognitive deficits of THC can be
dissociated from its beneficial antinociceptive properties.
Results
5-HT2AR Modulates THC’s Effects on Acute Amnesia, Anxiety, and
Social Interaction and Its Effect on Dorsal Raphe Neuronal Activity
Due to the compelling data that 5-HT2AR may interact with CB1R, we sought to broadly iden-
tify which behavioral effects of THC might be dependent on 5-HT2AR. Using wild-type (WT)
and 5-HT2AR knockout (KO) animals, we evaluated THC’s amnesic-like effects at two doses (3
and 10 mg/kg) known to induce memory deficits in the novel object recognition paradigm [1].
Acute THC administration of both doses of THC induced amnesic-like effects in WT mice,
and this effect was significantly reduced in 5-HT2AR KO animals only at the dose of 3 mg/kg
(Fig 1A), suggesting that 5-HT2AR increases the potency of THC to induce memory impair-
ments. Previous studies have shown that cannabinoid agonists can induce anxiogenic and anxi-
olytic-like responses in rodents, depending on the dose and the environmental conditions
[3,7]. Low doses of cannabinoids usually induce an anxiolytic-like effect, whereas higher doses
cause the opposite response. Using the previous reported dose of 0.3 mg/kg, we evaluated the
involvement of 5-HT2AR in the anxiolytic-like effects of THC [32]. Acute administration of
THC induced an anxiolytic-like effect in WT animals, while in KO mice this response was
reduced (Fig 1B). In agreement, a similar acute low dose of THC increased social interaction in
WTmice, whereas it decreased this response in KO animals (Fig 1C). Since anxiolytic-like
behavior has been associated with changes in the activity of dorsal raphe (DR) neurons [33],
we determined whether variations in DR neuronal activity induced by THC were modified in
5-HT2AR KO mice using extracellular electrophysiological recordings in slice preparations of
DR nucleus (Fig 1D). Basal activity of DR neurons was not modified in KO with respect to WT
mice (Fig 1F), indicating that 5-HT2AR do not exert a tonic modulation of serotonergic activity
in the DR nucleus, in line with previous microdialysis data showing similar basal extracellular
levels of 5-HT in the cortex of both genotypes [34]. However, KO animals were less sensitive
than WTmice to the decrease in neuronal firing evoked by THC (1 nM), an effect lost at a
higher THC concentration (10 nM), probably because of a ceiling effect (Fig 1E). These data
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Fig 1. 5-HT2ARmediates THC-induced amnesic- and anxiolytic-like effects. (A) The administration of THC (3 and 10 mg/kg) induced memory
impairments in the novel object recognition test in WTmice as compared to vehicle (VEH) treatment (n = 8–11), and this effect was significantly abrogated in
5-HT2AR KOmice at the dose of 3 mg/kg, but not at the dose of 10 mg/kg. (B) The anxiolytic effects of THC (0.3 mg/kg) observed in WTmice tested in the
elevated plus maze were blocked in 5-HT2AR KOmice (n = 9–12). (C) The increase in social interaction induced by THC (0.3 mg/kg) in WTmice was
abolished in 5-HT2AR KOmice (n = 5–7). (D) Neuronal firing of representative dorsal raphe (DR) neurons before and after THC administration (1 and 10 nM)
in WT (upper panel) and 5-HT2AR KO (lower panel) animals. (E) A challenge with THC (1 nM) reduced the percent change in firing rate of DR neurons from
WTmice, and this effect was blunted in DR neurons from 5-HT2AR KOmice. No significant differences between genotypes were observed following a
challenge with THC at 10 nM (n = 7–14). (F) The basal firing rate of DR neurons was similar in WT and 5-HT2AR KO animals (n = 20–24). (G–I) Withdrawal
symptoms, including paw tremor (G), sniffing (H), and global withdrawal score (GWS) (I), were reduced in 5-HT2AR KOmice when compared to WTmice.
Data are mean + standard error of the mean (SEM). * p < 0.05, ** p < 0.01, and *** p < 0.001 versus VEH; # p < 0.05 versusWTmice. The statistical
analyses used and their corresponding F and p-values are shown in S1 Table.
doi:10.1371/journal.pbio.1002194.g001
CB1R-5-HT2AR Heteromers Mediate THC-Induced Cognitive Deficits
PLOS Biology | DOI:10.1371/journal.pbio.1002194 July 9, 2015 4 / 40
suggest that specific effects of THC such as memory deficits, anxiolytic-like effects, social inter-
action, and DR neuronal activity are under the control of 5-HT2AR.
We also evaluated the role of 5-HT2AR in responses to chronic THC exposure. Rimona-
bant-precipitated THC withdrawal syndrome was evaluated in 5-HT2AR KOmice after chronic
THC treatment. Several somatic signs of abstinence including paw tremor (Fig 1G) and sniffing
(Fig 1H) were significantly attenuated in 5-HT2AR KO mice compared to WT animals, as well
as the global withdrawal score (GWS) calculated by giving each sign a proportional weight
(Fig 1I), indicating that 5-HT2AR is necessary for the full expression of THC withdrawal. Next,
we assessed by western blot analysis whether CB1R levels were modified in 5-HT2AR KOmice
following chronic treatment with THC. As a first step, we verified the specificity of the CB1R
antibody (S1A Fig) in naïve WT and KOmice. These results show that CB1R are expressed at
high levels in the cortex, striatum, nucleus accumbens, and hippocampus of WT mice but are
virtually absent in KO mice. In animals chronically treated with THC, CB1R levels decreased in
the hippocampus (S1B Fig) and cerebellum (S1C Fig) of both WT and KO, in agreement with
previous data [35]. In the hippocampus, but not in the cerebellum, this receptor down-
regulation was greater in KO mice than in WT mice treated with THC. In addition, we deter-
mined the state of the endocannabinoid system in KO mice as a control. Anandamide levels
were slightly but significantly reduced (S1D Fig), while 2-arachidonoylglycerol levels were not
modified in KO mice versus WTmice (S1E Fig). These findings highlight the key role played
by hippocampal 5-HT2AR in the adaptive responses induced by chronic THC exposure.
5-HT2AR Does Not Affect the Hypolocomotor, Hypothermic, Anxiogenic,
and Analgesic Effects of THC or the Reinforcing Effects of Cannabinoid
Agonists
Following the above-described differential effects in WT and 5-HT2AR KO animals in memory
and social phenotypes, we next sought to explore other behaviors to appreciate how general the
influence of 5-HT2AR is on THC's effects. Surprisingly, THC decreased locomotor activity in a
similar dose-dependent manner in WT and KOmice (Fig 2A). Likewise, THC reduced body
temperature dose-dependently and induced a profound hypothermia at 10 mg/kg in both
genotypes (Fig 2B). Next, we determined the antinociceptive effects of THC inWT and KO
mice using two different behavioral tests, namely, the tail-immersion and hot-plate tests. In the
tail-immersion test, THC induced a comparable dose-dependent analgesic effect in WT and
KOmice (Fig 2C). Similarly, the antinociception observed in the hot-plate test in terms of fore-
paw licking (Fig 2D) and jumping (Fig 2E) responses was comparable in WT and KOmice. To
evaluate THC-induced anxiogenic-like behavior, we used the dose of 3 mg/kg, in order to
avoid the locomotor suppressant effects of THC at higher doses. The acute administration of
this dose induced an anxiogenic-like response in both WT and KOmice as revealed by a
decrease in the percentage of time spent in the open arms of the elevated plus maze, with simi-
lar extent in both WT and KOmice (Fig 2F). Finally, the reinforcing properties of the CB1R
agonist, WIN 55,212–2, were investigated using the intravenous operant self-administration
model [36], which is the most reliable paradigm in rodents to evaluate the addictive potential
of drugs of abuse [37]. Both WT and KOmice learned to discriminate between the active and
inactive nose pokes and self-administered WIN 55,212–2 in a similar manner, indicating that
5-HT2AR does not play a role in the reinforcing properties of this cannabinoid agonist (Fig
2G), in contrast to the role played by this receptor on the reinforcing properties of psychosti-
mulants [34]. Together, our behavioral data comparing THC's effects in WT and 5-HT2AR KO
animals strongly point to a cross talk between CB1R and 5-HT2AR, particularly at the level of
memory, anxiolytic-like behavior, social interaction, and withdrawal syndrome.
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Fig 2. 5-HT2AR does not mediate THC-induced hypolocomotion, hypothermia, analgesia, anxiogenic-like behavior, or the reinforcing properties of
WIN 55,212–2. (A) Locomotor activity (% of baseline) was dose-dependently reduced in both WT and 5-HT2AR KOmice treated with THC (0.3, 1, 3, and 10
mg/kg) as compared to vehicle (VEH) administration (n = 5–15). (B) THC induced hypothermia at the dose of 10 mg/kg to a similar extent in WT and 5-HT2AR
KOmice (n = 13–24). (C) In the tail-immersion test, percent analgesia was dose-dependently increased by THC (1, 3, and 10 mg/kg) in both WT and
5-HT2AR KOmice (n = 10–16). In the hot-plate test, the percent of analgesia as calculated from the latency to paw-licking (D) and to jumping behavior (E)
was similar in WT and KO animals treated with THC (1, 3, and 10 mg/kg) as compared to VEH administration (n = 7–16). (F) No significant differences
CB1R-5-HT2AR Heteromers Mediate THC-Induced Cognitive Deficits
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Coexpression of 5-HT2AR and CB1R Causes Cell Signaling via Gi
Next, we sought to explore at the cellular level how 5-HT2AR and CB1R might achieve the
above-described cross talk between receptors. We first measured the global cellular response
using dynamic mass redistribution (DMR) label-free assays, which detect changes in light dif-
fraction in the bottom 150 nm of a cell monolayer [38]. Both CB1R agonists, THC and WIN
55,212–2, induced dose- and time-dependent signaling in cells only expressing CB1R (S2A
Fig). The 5-HT2AR receptor agonist DOI was unable to signal, and the antagonist MDL100,
907 was unable to revert the WIN 55,212-2-induced signal in cells expressing CB1R (S2B Fig).
The 5-HT2AR agonists, DOI and serotonin, induced dose- and time-dependent signaling in
cells only expressing 5-HT2AR (S2C Fig). Furthermore, WIN 55,212–2 was unable to signal,
and the antagonist rimonabant was unable to revert the DOI-induced signaling in cells express-
ing 5-HT2AR (S2D Fig), demonstrating the selectivity of the ligands. In cells stably expressing
CB1R, WIN 55,212–2 induced a time-dependent cell signal that was inhibited by pertussis
toxin (PTX), but not by cholera toxin (CTX) (S3A Fig), confirming that CB1R are coupled to
Gi in these cells [39]. Accordingly, WIN 55,212–2 reduced the forskolin-induced cyclic adeno-
sine monophosphate (cAMP), an effect blocked by PTX, but not by CTX or the Gq inhibitor
YM-254890 (S3B Fig). In cells only expressing 5-HT2AR, the cell signal induced by DOI was
not blocked by CTX or PTX, suggesting something other than a Gi or Gs coupling (S3C Fig).
Moreover, DOI was not able to increase cAMP or decrease forskolin-induced cAMP (S3D Fig),
bolstering previous studies showing that 5-HT2AR is coupled to Gq. In agreement, the Gq
inhibitor YM-254890 completely blocked the cell response to DOI (S3E Fig). DOI was able to
induce intracellular calcium release in these cells, an effect that was blocked by YM-254890
(S3F Fig), confirming that when expressed alone, 5-HT2AR are coupled to a Gq protein. Impor-
tantly, in cells coexpressing CB1R and 5-HT2AR, the DMR signal induced by both WIN
55,212–2 and DOI was inhibited by PTX, but not by CTX (Fig 3A). The Gq inhibitor, YM-
254890, had no effect on DOI signaling (Fig 3B), and neither DOI nor WIN 55,212–2 induced
intracellular calcium release in these cells (Fig 3C). These results suggest that coexpression of
CB1R and 5-HT2AR causes Gi coupling. Thus, blocking of Gi is sufficient to block receptor sig-
naling. To further support this finding, we measured changes in cAMP production upon recep-
tor activation. In cells expressing CB1R and 5-HT2AR, both WIN 55,212–2 and DOI
treatments led to a reduction in forskolin-activated cAMP production, and the effect of both
ligands was sensitive to PTX, but not to CTX (Fig 3D). In addition, WIN 55,212–2 or DOI
alone, in the absence of forskolin, did not modify cAMP in these cells (Fig 3D). This change of
G-protein coupling of 5-HT2AR by coexpression of CB1R suggests the formation of CB1R-
5-HT2AR heteromers.
CB1R and 5-HT2AR Form Heteromers
CB1R and 5-HT2AR have been traditionally considered as monomeric structural units that are
coupled to intracellular heterotrimeric G-proteins. More recent evidence suggests that they can
also assemble into homomers or heteromers with other G protein-coupled receptors (GPCRs)
[40,41]. We hypothesized, based on the above results, that CB1R and 5-HT2AR form heteromers
and their different expression in brain regions might account for the dissociation of THC behav-
ioral responses. To test this hypothesis, we first used a bioluminescent resonance energy transfer
between genotypes were observed in anxiogenic-like behavior induced by THC (3 mg/kg) (n = 6–10). (G) Both WT and 5-HT2AR KOmice acquiredWIN
55,212–2 self-administration behavior and responded equally for this drug during the 12 d of training (n = 12–15). Data are mean + SEM. * p < 0.05, **
p < 0.01, and *** p < 0.001 versus VEH-treated animals. The statistical analyses used and their corresponding F and p-values are shown in S1 Table.
doi:10.1371/journal.pbio.1002194.g002
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Fig 3. CB1R and 5-HT2AR are associated to Gi signaling when coexpressed. HEK-293Tcells expressing CB1R and 5-HT2AR receptors were used. In
(A and B), the DMR analysis was performed. In (A), cells were pretreated overnight with medium (black line), with 10 ng/ml pertussis toxin (purple line), or
with 100 ng/ml cholera toxin (yellow line) and were stimulated with 100 nM DOI. Alternatively, cells pretreated overnight with medium (red line), with 10 ng/ml
pertussis toxin (green line), or with 100 ng/ml cholera toxin (blue line) were stimulated with 50 nMWIN 55,212–2. In (B), cells were pretreated 30 min with
medium (black line) or with 1 μM of the Gq protein inhibitor YM-254890 (orange line) and were stimulated with 100 nM DOI. In all cases, the resulting
CB1R-5-HT2AR Heteromers Mediate THC-Induced Cognitive Deficits
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(BRET) assay. This assay has been well established for studying GPCR interactions and has the
advantage over classical immunoprecipitation approaches that it is performed in live cells over a
range of protein expression levels [42,43]. A saturable BRET curve (BRET-max of 64 ± 8 milli
BRET unit [mBU] and BRET50 of 4 ± 2) in cells expressing a constant amount of 5-HT2AR—
renilla luciferase (Rluc) and increasing amounts of CB1R yellow fluorescent protein (YFP) was
obtained (Fig 4A), indicating a specific interaction. Low and linear plots were observed using
either dopamine D1R-Rluc as the donor or adenosine A1R-YFP as the acceptor as negative con-
trols (Fig 4A), results consistent with nonspecific interactions [43]. These results indicate that
5-HT2AR and CB1R can form heteromers when coexpressed in cells. Further support for hetero-
mer formation was obtained by bimolecular fluorescence complementation (BiFC) assays out-
lined in Fig 4B. In this assay, fluorescence only appears after correct folding of two YFP Venus
hemiproteins. This occurs when two receptors fused to hemi-YFP Venus proteins (cYFP or
nYFP) come within proximity. Fluorescence was detected in HEK-293T cells transfected with
different amounts of cDNA corresponding to both 5-HT2AR-cYFP and CB1R-nYFP, but not in
negative controls in which cells were transfected with cDNA corresponding to 5-HT2AR-cYFP
and the noninteracting A1R-nYFP or CB1R-nYFP and the noninteracting D1R-cYFP (Fig 4B).
Finally, in a third technique, we provided additional evidence of heteromer formation via prox-
imity ligation assays (PLAs). This technique permits the direct detection of molecular interac-
tions between two endogenous proteins or transfected proteins, without the need of fusion
proteins. This technique is similar to immunoprecipitation but has an additional advantage of
not requiring membrane solubilization. Labeling heterodimers by PLA requires both receptors
to be sufficiently close to allow the two antibody-DNA probes to form double stranded segments
(<17 nm), a signal that is further amplified in the presence of fluorescent nucleotides [44].
CB1R-5-HT2AR heteromers were observed as green punctate staining in HEK-293T cells coex-
pressing CB1R and 5-HT2AR (Fig 4C), but not in negative controls in HEK-293T cells express-
ing CB1 and D1 receptors or for the noninteracting CB1 and transferrin receptors, in spite of the
expression and high colocalization of these pairs at the membrane level (S4A and S4B Fig). Also
as a negative control, no PLA staining was detected in samples in which cells only expressing
CB1R or 5-HT2AR alone were mixed at a 1:1 ratio (S4C Fig). Previous studies have shown PLA
to be semiquantitative and particularly useful at lower expression levels [45]. To estimate the rel-
ative sensitivity of the PLA for GPCRs, experiments were performed in cells transfected with
increasing cDNA amounts of 5-HT2AR and CB1R. In each case, PLA was quantified as the ratio
between the number of green spots and the number of cells expressing spots (ratio r). This ratio
was then represented as a function of the receptor’s cDNA transfected (Fig 4D). We observed
an increase in PLA signal with increasing cDNA (Fig 4D.) These three independent approaches
provide strong support for the formation of CB1R-5-HT2AR heteromers.
Functional Characteristics of CB1R-5-HT2AR Heteromers
A common consequence of heteromer formation is altered downstream signaling upon dual
stimulation of the receptors in the heteromer [46–48]. To examine whether this may be the
picometer shifts of reflected light wavelength (pm) were monitored over time. Each curve is the mean of a representative optical trace experiment carried out
in triplicates. In (C), intracellular calcium release was monitored in cells expressing CB1R and 5-HT2AR receptors treated with 100 nM DOI (black curve) or
with 50 nMWIN 55,212–2 (red curve). Values are mean ± SEM of n = 3. In (D), cAMP production was determined in cells treated with medium (control),
treated overnight with 10 ng/ml pertussis toxin (PTX), or treated 1 h with 100 ng/ml cholera toxin (CTX). Cells were stimulated with 100 nM DOI or 100 nM
WIN 55,212–2 (WIN) in the absence or in the presence of 0.5 μM forskolin (FK). Values (cAMP produced in each condition minus basal stimulation in the
absence of forskolin or agonists) represent mean ± SEM of n = 3–4 and are expressed as the percentage of the forskolin-treated cells in each conditions
(120–150 pmols cAMP/106 cells). One-way ANOVA followed by a Dunnett’s multiple comparison test showed a significant effect over the forskolin-alone
effect in each condition (* p < 0.05, ** p < 0.01).
doi:10.1371/journal.pbio.1002194.g003
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Fig 4. 5-HT2AR and CB1R form heteromers in transfected cells. In (A), BRET saturation experiments were performed in HEK-293T cells transfected with
0.025 μg of 5-HT2AR-Rluc cDNA and increasing amounts of CB1R-YFP cDNA (0.05 μg to 1.5 μg, black curve), with 0.5 μg of dopamine D1R-Rluc cDNA and
increasing amounts of CB1R-YFP cDNA (0.5 μg to 6 μg, yellow line), or with 0.025 μg of 5-HT2AR-Rluc cDNA and increasing amounts of adenosine A1R-YFP
cDNA (0.05 μg to 1.5 μg, red line). The relative amount of BRET is given as a function of 100 x the ratio between the fluorescence of the acceptor (YFP) and
the luciferase activity of the donor (Rluc). BRET is expressed as milli BRET units (mBU) and is given as the mean ± standard deviation (SD) of 3–6
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case for CB1R-5-HT2AR- heteromers, we determined signaling through adenylate cyclase,
arrestin recruitment, the ERK 1/2 pathway, and the Akt pathway in cells expressing both recep-
tors. In cells stimulated with forskolin and treated with WIN 55,212–2, DOI, or both, we found
that costimulation led to reduced cAMP production (Fig 5A). To examine whether costimula-
tion led to changes in β-arrestin II recruitment compared to single stimulation, the agonist-
induced interaction of arrestin with the receptors was measured by BRET in cells expressing β-
arrestin II-Rluc, 5-HT2AR-YFP, and CB1R. Both agonists, DOI and WIN 55,212–2, recruited
β-arrestin II, but costimulation led to a significant decrease in arrestin recruitment (Fig 5B),
indicating that costimulation reduces cell signaling. Both CB1R and 5-HT2AR agonists induced
the activation of ERK 1/2 and Akt pathways in a time- and dose-dependent manner (S5 Fig).
Measuring ERK 1/2 phosphorylation (Fig 5C) or Akt phosphorylation (Fig 5D), the costimula-
tion with WIN 55,212–2 and DOI, surprisingly, did not increase the phosphorylation levels
reached by each agonist separately. This response was not due to a change in the optimum
time response for ERK 1/2 (S6A Fig) or Akt phosphorylation (S6B Fig). Taken together, these
data suggest that costimulation of CB1R-5-HT2AR heteromers leads to reduced cell signaling.
Some GPCR heteromers have been found to display cross antagonism, the ability of an antago-
nist of one receptor to antagonize the signaling of the partner receptor [49,50]. Cross antago-
nism requires direct protein—protein interaction since antagonists do not signal on their own.
When cells coexpressing both receptors were pretreated with the CB1R antagonist rimonabant
and then stimulated with the CB1R agonist WIN 55,212–2 or the 5-HT2AR agonist DOI, sur-
prisingly no decreases in cAMP (Fig 5E), no β-arrestin II recruitment (Fig 5F), and no phos-
pho-ERK 1/2 (Fig 5G) or phospho-Akt (Fig 5H) were observed. These results indicate that
rimonabant blocks both CB1R and 5-HT2AR signaling. Analogously, the signaling in cAMP
(Fig 5E), β-arrestin II recruitment (Fig 5F), and phospho-ERK 1/2 (Fig 5G) or phospho-Akt
(Fig 5H) induced by both the CB1R agonist WIN 55,212–2 and the 5-HT2AR agonist DOI were
completely blocked when cells were pretreated with the 5-HT2AR antagonist MDL 100,907.
This cross antagonism is not due to the lack of specificity of the ligands since the 5-HT2AR ago-
nist DOI and the antagonist MDL100,907 were unable to signal or modify the CB1R signaling
in cells only expressing CB1R (S6C Fig). Furthermore, the CB1R agonist WIN 55,212–2 and the
antagonist rimonabant did not modify the 5-HT2AR signaling in cells only expressing
5-HT2AR (S6D Fig). In total, these results demonstrate that CB1R-5-HT2AR heteromers display
bidirectional cross antagonism.
Molecular Basis of Cross Antagonism in CB1R-5-HT2AR Heteromers
To understand how receptor—receptor interactions might facilitate the above-mentioned cross
antagonism and to potentially design a biochemical tool to disrupt these interactions, we took
advantage of the exponential growth in the number of solved GPCR structures, in the form of
experiments grouped as a function of the amount of BRET acceptor. In (B), a schematic representation of fluorescence complementation experiments is
depicted in the left panel showing that fluorescence only appears after the YFP Venus hemiprotein complementation due to the proximity of two receptors
fused to hemi-YFP Venus proteins (cYFP or nYFP). In the right panel, fluorescence at 530 nm was detected in HEK-293T cells transfected with different
amounts of cDNA corresponding to both 5-HT2AR-cYFP and CB1R-nYFP (equal amount for each construct), but not in negative controls in which cells were
transfected with cDNA corresponding to 5-HT2AR-cYFP and the noninteracting adenosine A1 receptor-nYFP or CB1R-nYFP and the noninteracting
dopamine D1 receptor-cYFP. One-way ANOVA followed by a Dunnett’s multiple comparison test showed a significant fluorescence over basal values in
HEK-293T cells (** p < 0.01, *** p < 0.001). In (C), PLAs were performed in HEK-293T cells expressing CB1R and 5-HT2AR. Confocal microscopy images
(superimposed sections) are shown in which heteromers appear as green spots. In all cases, cell nuclei were stained with DAPI (blue). Scale bars = 20 μm.
In (D), PLAs were performed in nontransfected HEK-293T cells, cells transiently transfected with 0.5 μg of CB1R or 5-HT2AR cDNA (negative controls, white
columns), or with increasing amounts of CB1R and 5-HT2AR cDNA (black columns). In each case, the ratio between the number of green spots and the
number of cells showing spots (ratio r) was calculated. One-way ANOVA followed by a Dunnett’s multiple comparison test showed a significant PLA staining
over nontranfected cells (*** p < 0.001).
doi:10.1371/journal.pbio.1002194.g004
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Fig 5. A profile of CB1R-5-HT2AR heteromer signaling. In (A and E), cAMP production was determined in HEK-293Tcells expressing CB1R and 5-HT2AR
after stimulation with 100 nM DOI, 100 nMWIN 55,212–2 (WIN), or both in the absence or in the presence of 0.5 μM forskolin. In (E), cells were first
preincubated either with the CB1R antagonist rimonabant (1 μM, RIM) or the 5-HT2AR antagonist MDL 100,907 (300 nM) for 20 min prior to being stimulated.
Values (cAMP produced in each condition minus basal stimulation in the absence of forskolin or agonists) represent mean ± SEM of n = 3–4 and are
expressed as the percentage of the forskolin-treated cells in each condition (120–150 pmols cAMP/106 cells). One-way ANOVA followed by a Bonferroni
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monomers or homo-oligomers, bound to either agonists, antagonists, inverse agonists, or in
complex with the G-protein to model heteromer activation (S7 Fig) [51]. Agonist binding at
the extracellular side triggers small local structural changes near the binding site [52] that are
translated into larger-scale helix movements at the intracellular site [53]. Specifically, agonists
increase signaling by opening an intracellular cavity, required for the binding of the C-terminal
α5 helix of the G-protein, through the movement of TM 5 and TM 6. Conversely, inverse ago-
nists decrease the basal, agonist-independent level of signaling by closing this cavity. Our find-
ings that CB1R-5-HT2AR heteromers display bidirectional cross antagonism led us to suggest
that the antagonist-bound conformation of protomer A allosterically prevents the opening of
the intracellular cavity of protomer B. To our knowledge, the molecular basis of this bidirec-
tional cross antagonism has not been described. Recently, the crystal structure of the μ-opioid
receptor has shown a novel mode of receptor dimerization via TMs 5 and 6 [54]. In this assem-
bly, TMs 5 and 6 of protomer A form a very stable four-helix bundle with TMs 5 and 6 of pro-
tomer B (S7A Fig). This high surface complementarity in the heteromer, within the four-helix
bundle interface, prevents the opening of the intracellular cavity (S7A Fig). Thus, we hypothe-
sized that bidirectional cross antagonism in the CB1R-5-HT2AR heteromer is due to antagonist
binding to either protomer that stabilizes the inactive conformation of TM 5 and TM 6 and to
the subsequent formation of this very stable four-helix association. As a consequence, the
action of agonists is blocked at both receptors (see Fig 6A–6D for details). To test this hypothe-
sis, we investigated if synthetic peptides with the sequence of TMs 5, 6, and 7 (as negative con-
trol) of CB1R, fused to HIV TAT, were able to disrupt receptor heterodimerization and the
observed bidirectional cross antagonism. This approach has been used by us and others previ-
ously [55,56]. We first checked by immunocytochemistry that TM 5, TM 6, and TM 7 interfer-
ence peptides do not appreciably change the expression and colocalization of CB1R and
5-HT2AR at the membrane level (S8 Fig). We found that pretreatment with TM 5 and TM 6
(but not TM 7) interference peptides of cells expressing CB1R-nYFP and 5-HT2AR-cYFP dis-
rupt the heteromer structure as revealed by a loss of fluorescence in BiFC assays (S9 Fig). These
results were further confirmed by PLA assays. CB1R-5-HT2AR heteromers were observed as
green punctate staining in HEK-293T cells not treated or treated with the TM 7 interference
peptide, but they were absent in cells treated with TM 5 or TM 6 interference peptides (Fig
7A). Notably, the cross antagonism was not observed at the level of cAMP (Fig 7B), ERK 1/2
phosphorylation (Fig 7C), and Akt phosphorylation (Fig 7D) in HEK-293T cells expressing
CB1R and 5-HT2AR and treated with TM 5 or 6 peptides. The effect of the peptides was specific
to the heteromer, as single activation of the individual receptors still led to signaling in the
presence of the peptides. Importantly, these results indicate that negative cross talk and cross
antagonism require receptor—receptor interaction and are specific biochemical characteristics
of the heteromer that can be used as a fingerprint to detect the heteromer [47,49,57]. These
results suggest that receptor heterodimerization occurs via TM 5 and TM 6, which facilitates
post hoc tests showed a significant effect over the forskolin-alone effect in each condition (** p < 0.01, *** p <0.001) or of the antagonist plus agonist
treatment over the agonist treatment (# p < 0.05, ## p < 0.01, ### p < 0.001). In (B and F), β arrestin II recruitment was measured by BRET experiments in
cells transfected with 2 μg of CB1R cDNA, 0.2 μg of β-arrestin II-Rluc cDNA, and 1 μg of 5-H2AR-YFP cDNA. Cells were not preincubated with antagonist (B)
or were preincubated (F) for 20 min with vehicle, rimonabant (1 μM, RIM), or MDL 100,907 (300 nM, MDL). Cells were not treated (BRET < 10) or were
treated for 7 min with WIN 55,212–2 (100 nM, WIN) or DOI (100 nM) before BRET determination. Values represent mean ± SEM of n = 4–6. One-way
ANOVA followed by a Bonferroni post hoc tests showed a significant effect over not-treated cells (* p < 0.05, ** p < 0.01, *** p <0.001) or of the antagonist
plus agonist treatment over the agonist treatment (## p < 0.01, ### p < 0.001). In (C, D, G, and H), cells expressing CB1R and 5-HT2AR were not
preincubated with antagonist (C and D) or were preincubated for 15 min with rimonabant (1 μM, RIM) or MDL 100,907 (300 nM, MDL) (G and H) and
stimulated for 5 min with WIN 55,212–2 (100 nM,WIN) or DOI (100 nM). Quantification of phosphorylated ERK 1/2 (C and G) or Akt (D and H) was determined
by western blot. Values, expressed as percentage of basal (nontreated cells), were mean ± SEM of n = 3–10. One-way ANOVA followed by a Bonferroni post
hoc tests showed a significant effect over basal (* p < 0.05, ** p < 0.01, ** p < 0.001) or of the antagonist plus agonist treatment over the agonist treatment
(# p < 0.05, ## p < 0.01, ### p < 0.001).
doi:10.1371/journal.pbio.1002194.g005
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the observed cross antagonism. GPCRs are dynamic proteins that permit rapid small-scale
structural fluctuations and pass through an energy landscape to adopt a number of conforma-
tions ranging from inactive to active. Our results have shown that in the case of receptor het-
erodimerization via TM 5 and TM 6, one of the protomers allosterically modulates the
functional properties (energy landscape) of the interacting receptor (S7B Fig).
Differential Expression of Functional CB1R-5-HT2AR Heteromers in the
Brain
CB1R-5-HT2AR heteromer expression in tissue was analyzed by in situ PLA using specific pri-
mary antibodies directed against CB1R and 5-HT2AR that have been validated in WT, CB1R
KO, and 5-HT2AR KOmice (Fig 8) [58]. CB1R-5-HT2AR heteromers were observed as punc-
tate green spots in cells with DAPI-stained nuclei in slices from hippocampus (CA3 region),
dorsal striatum (caudate-putamen), and cortex (somatomotor layers 1, 2, and 3), all areas
where both receptors are expressed [13], of WT animals, but not in 5-HT2AR or CB1R KO ani-
mals (Fig 8A) or in negative controls (S10 Fig). In all cases, staining was observed in a relatively
high percentage of cells (60%–70%) (Fig 8B). Interestingly, no green spots were detected in
slices from nucleus accumbens in either WT or KO animals, indicating a differential expression
of heteromers in the brain (Fig 8). To further support the existence of heteromer expression in
these brain regions, we used the heteromer specific biochemical characteristics identified above
(negative cross talk and cross antagonism) as a heteromer fingerprint to detect heteromers in
situ. We measured ERK 1/2 phosphorylation in isolated brain slices from the hippocampus
Fig 6. Proposed functional properties of CB1R-5-HT2AR heteromers. In (A), agonist binding to CB1R
(blue) or 5-HT2AR (light green) triggers the conformational changes of TMs 5 and 6, opening the intracellular
cavity for Gi and Gq binding, respectively. In (B), the formation of the CB1R-5-HT2AR heteromer makes both
receptors signal via Gi. In (C), rimonabant binding to CB1R or MDL 100,907 to 5-HT2AR stabilizes the closed
conformation of the receptor, facilitating heterodimerization via TMs 5 and 6 as in the crystal structure of
the μ-opioid receptor. In this assembly, both protomers are locked in the closed conformation since the
opening of TMs 5 and 6 for G-protein binding is not feasible (see S7 Fig). Bidirectional cross antagonism is
due to the fact that antagonist binding to any protomer must, in addition to its common role in a monomeric
signaling unit, disrupt this very stable four-helix association. (D) In agreement, bidirectional cross antagonism
is abrogated following treatment with TM 5 or TM 6 interference peptides (dark blue), which disrupt the
heteromer structure.
doi:10.1371/journal.pbio.1002194.g006
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Fig 7. Interacting protomer domains in CB1R-5-HT2AR heteromers and heteromer disruption by TM interference peptides. In (A), HEK-293T cells
expressing CB1R and 5-HT2AR were treated for 4 h with vehicle (left panel) or 4 μM of CB1R TM 7, TM 5, or TM 6 interference peptides before performing
proximity ligation assays. Confocal microscopy images (superimposed sections) are shown in which heteromers appear as green spots in cells treated with
vehicle and with TM 7 interference peptide, but not in cells treated with TM 5 or TM 6 interference peptides. In all cases, cell nuclei were stained with DAPI
(blue). Scale bars = 20 μm. In (B–D), HEK-293T cells expressing CB1R and 5-HT2AR were preincubated for 20 min with rimonabant (1 μM, RIM) or MDL
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(Fig 9A), dorsal striatum (Fig 9B), cortex (Fig 9C), or nucleus accumbens (Fig 9D) of WT mice.
As expected when slices were treated with WIN 55,212–2 or DOI, ERK 1/2 phosphorylation
was induced. As in cells, hippocampal, dorsal striatal, and cortical cell signaling was not
increased when slices were coactivated with both agonists, again suggesting reduced signaling
100,907 (300 nM, MDL) before stimulation for 10 min (B) or 5 min (C, D) with the CB1R agonist WIN 55,212–2 (100 nM), the 5-HT2AR agonist DOI (100 nM),
or both in the presence (B) or absence (C, D) of 0.5 μM forskolin. In (B), cAMP production was determined. Values represent mean ± SEM of n = 3–9 and are
expressed as the percentage of the cAMP produced in forskolin-treated cells. Quantification of phosphorylated ERK 1/2 (C) or Akt (D) was determined by
western blot. Values, expressed as a percentage of basal (nontreated cells), were mean ± SEM of n = 3–6. One-way ANOVA followed by a Bonferroni post
hoc tests showed a significant effect over forskolin’s effects alone in each condition (B) or over basal (C, D) (* p < 0.05, ** p < 0.01, *** p <0.001) or of the
antagonist plus agonist treatment over the agonist treatment (# p < 0.05, ## p < 0.01, ### p < 0.001).
doi:10.1371/journal.pbio.1002194.g007
Fig 8. Differential expression of CB1R-5-HT2AR heteromers in the brain detected by in situ PLAs. In (A), PLAs were performed using slices of mouse
hippocampus CA3, caudate-putamen (striatum), cortex (somatomotor layers 1, 2, and 3) or nucleus accumbens (NaC). Confocal microscopy images
(superimposed sections) are shown in which heteromers appear as green spots in WTmice, but not in 5-HT2AR KO or CB1R KOmice in the hippocampus,
caudate-putamen, and cortex. Any staining was observed in the nucleus accumbens of either WT or KO animals. In all cases, cell nuclei were stained with
DAPI (blue). Scale bars = 20 μm. In (B), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells
(blue nucleus) in the hippocampus, striatum, cortex, and nucleus accumbens of WT (white bars), 5-HT2AR KO (black bars), or CB1R KO (grey bars) mice.
Data (percentage of positive cells) are the mean ± SEM of counts in 4–9 different fields (see experimental procedures). Student’s t test showed a significant
effect over 5-HT2AR KO or over CB1R KOmice in each condition (*** p < 0.001).
doi:10.1371/journal.pbio.1002194.g008
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Fig 9. Differential expression of CB1R-5-HT2AR heteromers in the brain detected by heteromer
signaling. Slices from the hippocampus (A), caudate-putamen (B), cortex (C), and nucleus accumbens (D)
of WTmice (white bars) and 5-HT2AR KOmice (black bars) were preincubated or not with CB1R antagonist
rimonabant (1 μM, RIM) or the 5-HT2AR antagonist MDL 100,907 (300 nM, MDL) for 20 min before the
addition of the CB1R agonist WIN 55,212–2 (1 μM,WIN), the 5-HT2AR agonist DOI (1 μM), or both for an
CB1R-5-HT2AR Heteromers Mediate THC-Induced Cognitive Deficits
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(Fig 9A–9C, white bars). In addition, p-ERK 1/2 levels induced after treatment with DOI were
lowered when the slices were pretreated with the CB1R antagonist rimonabant, while the
5-HT2AR antagonist MDL 100,907 blocked the activation induced by WIN 55,212–2 (Fig 9A–
9C, white bars). This cross antagonism mirrors what was observed in transfected cells and
serves as biochemical evidence that heteromers are both expressed and functional. Importantly,
nucleus accumbens fromWTmice showed increased signaling upon dual stimulation and no
cross antagonism (Fig 9D, white bars), supporting the lack of expression of the heteromer as
previously observed by the lack of PLA staining. To confirm that the results were indeed due to
the expression of heteromers, we repeated the experiments in 5-HT2AR KOmice. No cross talk
or cross antagonism was observed in slices from the cortex, striatum, and hippocampus of KO
mice (Fig 9, black bars). The lack of heteromerization in the nucleus accumbens is not due to a
lack of receptor expression in this tissue since both agonists DOI and WIN 55,212–2 induced a
signal very similar to the one induced in the other brain regions, where the heteromer finger-
print or PLA staining was observed (Fig 9A–9D). The above results demonstrate the differen-
tial expression of functional CB1R-5-HT2AR heteromers in brain tissue.
CB1R-5-HT2AR Heteromers Are Involved in the Amnesic and Anxiolytic-
like Behavior Induced by THC
In order to implicate the involvement of the heteromer in the behavioral effects of THC in
vivo, we evaluated cross antagonism in WTmice. Thus, the effects of the 5-HT2AR antagonist
MDL 100,907 on THC-induced memory impairments using the object recognition test and on
its anxiolytic-like properties using the elevated plus maze were evaluated. THC (3 mg/kg)
induced significant memory impairments in vehicle-treated animals, but not in mice pretreated
with MDL 100,907 (0.01 mg/kg) (Fig 10A). We further confirmed that this effect was mediated
by the heteromer since THC-induced memory impairments were not observed in WT animals
previously treated with TM5 or TM6 peptides (0.2 μg/2 μl ICV) but were present in animals
receiving the TM7 peptide (Fig 10B). Similarly, THC-induced anxiolytic-like effects were pre-
vented by MDL 100,907 administration (Fig 10C) and by ICV infusion of TM5 and TM6 pep-
tides, but not by TM7 (Fig 10D). Importantly, using PLA we were able to demonstrate that
administration of TM5 and TM6, but not TM7, peptides was able to disrupt the heteromer in
vivo. In hippocampal CA3, striatal (caudate-putamen) or cortical (somatomotor layers 1, 2,
and 3) slices from mice treated with vehicle or TM7 peptide (0.2 μg/2μl ICV) heteromers
appear as green spots, a staining not seen in mice treated with equivalent amounts of TM6 pep-
tide (Fig 10E and 10F). These results demonstrate that CB1R-5-HT2AR heteromers are involved
in the amnesic and anxiolytic-like behavior induced by THC.
In support of the involvement of 5-HT2AR in only certain effects of THC, preadministration
(0.2 μg/2 μl ICV) of TM 5, TM 6, or TM 7 interference peptides did not change THC-induced
hypolocomotion (Fig 10G), hypothermia (Fig 10H), or analgesia (Fig 10I). This differential
effect was also observed when 5-HT2AR KOmice and WT littermates were compared (S11
Fig). Preadministration of TM 6, but not TM 7, peptides blocked the THC-induced changes in
the discrimination index and percent of time in open arms in WTmice (S11A and S11B Fig),
additional incubation period of 10 min. ERK 1/2 phosphorylation was determined by western blot.
Immunoreactive bands from three to seven slices obtained from ten WT or KO animals were quantified for
each condition. Values represent mean ± SEM of the percentage of phosphorylation relative to basal levels
found in untreated slices. No significant differences were obtained between the basal levels of the WT and
the KOmice. One-way ANOVA followed by Bonferroni post hoc tests showed a significant (* p < 0.05,
** p < 0.01, *** p < 0.001) effect over basal or of the antagonist plus agonist treatment over the agonist
treatment (# p < 0.05, ## p < 0.01).
doi:10.1371/journal.pbio.1002194.g009
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Fig 10. Prevention of THC-induced amnesic and anxiolytic-like effects by pharmacological blockade of 5-HT2AR or by CB1R-5-HT2AR heteromer
disruption with TM interference peptides. The amnesic effects of THC (3 mg/kg) observed in C57BL/6J mice in the novel object recognition test were
abrogated by pretreatment with the 5-HT2AR antagonist, MDL 100,907 (0.01 mg/kg) (A) and by pretreatment with TM 5 and TM 6, but not TM 7, interference
peptides (0.2 μg/ 2μl ICV) (B) (n = 5–9). The anxiolytic effects of THC (0.3 mg/kg) observed in the elevated plus maze in C57BL/6J mice were blocked by
pretreatment with the 5-HT2AR antagonist, MDL 100,907 (0.01 mg/kg) (C) and by pretreatment with TM 5 and TM 6, but not TM 7, interference peptides
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but neither TM 6 nor TM 7 altered the lack of effect of THC in KO mice (S11F and S11G Fig).
In both WT (S11C–S11E Fig) and 5-HT2AR KO (S11H–S11J Fig) mice, the effect of THC on
locomotion, body temperature, and analgesia was not altered by preadministration of TM 6 or
TM 7 peptides. These findings provide evidence for the in vivo requirement of the CB1R-
5-HT2AR heteromer to be intact in order to observe the amnesic and anxiolytic-like behavior
induced by THC but not in other THC-mediated effects.
Discussion
While exploring the neurobiological mechanisms underlying THC-induced cognitive
impairment, we discovered an unexpected role of the 5-HT2AR. Our findings lead to three
major conclusions. First, behavioral studies carried out in mice lacking 5-HT2AR revealed a
remarkable 5-HT2AR-dependent dissociation in the beneficial antinociceptive effects of THC
and its detrimental amnesic properties. Second, CB1R and 5-HT2AR form heteromers that are
expressed and functionally active in specific brain regions involved in memory impairment.
Third, to observe the negative cognitive effects of THC, these receptors must be functionally
interacting, as administration of a 5-HT2AR antagonist or selective disruption of the CB1R-
5-HT2AR heteromers by ICV infusion of synthetic interference peptides in WT mice abrogated
the memory deficits induced by THC and its anxiolytic-like effects, but not its antinociceptive
properties.
Previous studies have suggested interactions between endocannabinoids and 5-HT,
although the extent of this alleged reciprocal interaction and the molecular mechanisms
involved have been difficult to ascertain. Here we found that the amnesic, anxiolytic, and pro-
social-like effects induced by THC, as well as the manifestations of THC withdrawal syndrome,
were reduced in mice with constitutive deletions of 5-HT2AR. In contrast, 5-HT2AR deletion
did not modulate the acute hypolocomotor, hypothermic, anxiogenic, and antinociceptive
effects of THC or the reinforcing effects of the cannabinoid agonist, WIN 55,212–2. These data
demonstrate for the first time, to our knowledge, that 5-HT2AR modulates specific behavioral
responses related to CB1R activation by THC. There seemed to be three plausible explanations
for the differential effects of THC and its dependence on 5-HT2AR: (1) interactions only at the
level of circuitry, (2) circumstantial cross talk at the level of intracellular signaling, or (3) direct
protein—protein interaction that can modify receptor function. Although our study cannot
completely count out interactions at the level of circuitry, we have clearly observed cross talk in
transfected cells that would circumvent the need for circuitry connections. Indeed, both recep-
tors are coexpressed in the hippocampus, where they participate in memory processing
[16,17,59]. They are also colocalized in the cerebral cortex, hypothalamus, striatum, and
nucleus accumbens, brain areas implicated in reward processing and affective disorders,
including anxiety [60–63]. To delineate between circumstantial intracellular cross talk and
direct protein—protein interaction, we tested whether the receptors could form complexes if
coexpressed, which we found to be the case. We then were able to show that the signaling cross
(0.2 μg/ 2μl ICV) (D) (n = 4–11). The data represent mean + SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 versus vehicle, # p < 0.05 versus THC-treated mice.
In (E), PLA performed in hippocampal CA3, striatal (caudate-putamen), and cortical (somatomotor layers 1, 2, and 3) slices frommice treated with VEH, TM
6, and TM 7 interference peptides (0.2 μg/ 2μl ICV). Confocal microscopy images (superimposed sections) are shown in which heteromers appear as green
spots in VEH and TM 7-treated mice, but not in mice treated with TM 6 interference peptides. In all cases, cell nuclei were stained with DAPI (blue). Scale
bars = 20 μm. In (F), the number of cells containing one or more green spots is expressed as the percentage of the total number of cells (blue nucleus) in the
hippocampus, striatum, and cortex (top to bottom). Data (percentage of positive cells) are the mean ± SEM of counts in 8–12 different fields. *** p < 0.001
versus vehicle-treated mice. Pretreatment with TM 5, TM 6, or TM 7 peptides (0.2 μg/ 2μl ICV) had no significant effects on hypolocomotion (G), hypothermia
(H), or analgesia (I) induced by THC (10 mg/kg) in C57BL/6J mice. The statistical analyses used and their corresponding F and p-values are shown in S1
Table.
doi:10.1371/journal.pbio.1002194.g010
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talk observed required this receptor—receptor interaction both in vitro and in vivo. The disso-
ciation observed regarding the involvement of this heteromeric complex in the memory
impairments and the antinociception observed following THC administration were corrobo-
rated in our in vivo studies. When the heteromer was disrupted by ICV infusion of interference
peptides TM5 and TM6, we observed blunted amnesic and anxiolytic, but not antinociceptive,
effects of THC selectively in WT mice. Interference peptides have been successfully used in ear-
lier studies to ascertain the role of heterodimer formation in physiological functions [56] and
in behavioral models of mood disorders [64]. It appears then that serendipitous signaling cross
talk is not a sufficient explanation for the dependence on 5-HT2AR for THC’s effects. A more
plausible explanation might be that these receptors present different degrees of interaction
depending on the cell type or cell location. Such a scenario would predict the existence of dif-
ferent populations of CB1R. One population when stimulated with THC provides a certain
level of cellular signaling that impacts on neurons influencing locomotion or antinociceptive
effects, while a separate population of CB1R coupled to 5-HT2AR would provide altered cell sig-
naling upon exposure to THC that directly influences memory or anxiolytic-like effects. In
agreement, CB1R in glutamatergic cells have been recently reported to have a much higher cou-
pling to G-proteins than CB1R in GABAergic cells, sustaining the possibility of different func-
tional populations of the receptor [65]. Support for this idea is provided by our results showing
that 5-HT2AR and CB1R form heteromers in specific brain structures, such as the cortex, hip-
pocampus, and striatum, but not in the nucleus accumbens, a key structure of the reward cir-
cuit. Several drugs of abuse, including cannabis, increase dopamine release in the nucleus
accumbens [66], and an interaction between CB1R and dopamine D2 receptor signaling has
been suggested in this area [67]. Our results showing no heteromer formation in the nucleus
accumbens, together with the finding that 5-HT2AR does not modulate cannabinoid (WIN
55,212–2) reinforcing properties, suggest that these receptors are not involved in the modula-
tion of dopamine responses in this structure. Moreover, our data showing a reduction in p-
ERK 1/2 via the heteromer are particularly interesting since ERK signaling is important for
long-term synaptic plasticity [68], which plays a crucial role in learning and memory.
Although we are unable to speculate on the amount of heteromers in the different regions, it
is clear that the lack of heteromers in the nucleus accumbens is not due to lack of expression, as
both receptors were still able to signal upon receptor stimulation at levels equal to the other
brain regions. These data suggest that heteromer formation is not simply due to overexpression
of the receptors in these regions and that there exists a mechanism to regulate heteromer for-
mation within the brain. Differential expression levels of CB1R do not always correlate with the
ability to couple to G-proteins [65], which reinforces the idea that more subtle mechanisms are
at play than simple expression. The precise subcellular localization of this heteromeric popula-
tion of receptors is still not known. However, PLA positive elements could be revealing both
pre- and postsynaptic heterodimers, consistent with data showing that CB1R and 5-HT2AR are
colocalized at pre-and postsynaptic levels in different areas of the brain [16,18–27,69,70].
Furthermore, the ICV infusion technique ensured that CB1R-5-HT2AR heteromers were
disrupted by TM interference peptides in key brain areas mediating the observed effects since
most of these structures, including the hippocampus, dorsal raphe nucleus, and periaqueductal
grey, are in close proximity to the ventricles. Pharmacological targeting of heteromers is of
great interest, in part because the GPCR heteromers are unique signaling units with functional
properties different from homomers [40,71]. Indeed, our functional data show that costimula-
tion of CB1R-5-HT2AR heteromers by agonists reduces cell signaling, whereas antagonist bind-
ing to one of the receptors blocks the signaling of the interacting receptor (bidirectional cross
antagonism). Importantly, we also found that formation of the CB1R-5-HT2AR heteromers
presents a different G-protein coupling, with 5-HT2AR coupling to Gi instead of Gq, and a
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signaling profile different from the single receptors (similar results were previously seen with
the mGlu2R-5-HT2AR heteromer [72]). In pioneering work, the group of Kobilka has shown
that GPCRs are dynamic proteins, adopting a number of conformations through an energy
landscape [73]. Ligand or G-protein binding changes the shape of the energy landscape, favor-
ing or disfavoring the intracellular signal. Based on our findings, we propose that in the case of
GPCR heteromers one of the protomers allosterically modulates the functional properties of
the interacting receptor, and this can be conceptualized using energy landscapes (S7 Fig).
CB1R activation by cannabinoids such as THC produces a variety of negative effects, includ-
ing cognitive impairments [1,2] and anxiogenic- and addictive-like responses [5], which have
major consequences in cannabis users and constitute important drawbacks for the use of can-
nabinoids as therapeutic agents [74]. The genetic, molecular, and pharmacological data pre-
sented here demonstrate the requirement for CB1R-5-HT2AR heteromers for the negative
cognitive effects of THC. These heterocomplexes could be potentially modulated in the form of
disruption or by their selective pharmacological blockade in order to dissociate the cognitive
impairment induced by THC from its beneficial antinociceptive properties.
Materials and Methods
All the procedures involving animals were performed by observers blind to experimental con-
ditions following standard ethical guidelines (European Communities Directive 86/60-EEC)
and were approved by the local ethical committee (Comitè Ètic d'Experimentació Animal-Parc
de Recerca Biomèdica de Barcelona, CEEA-PRBB). The PRBB also has Animal Welfare Assur-
ance (#A5388-01, Institutional Animal Care and Use Committee approval date 06/08/2009)
granted by the Office of Laboratory Animal Welfare (OLAW) of the United States National
Institutes of Health. As of June 2010, the programme of care and use of laboratory animals at
the PRBB has the full accreditation from the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC). Mice were anesthetized with a mixture of ketamine/xyla-
zine and euthanized with carbon dioxide (concentrations between>70% and<100%).
Animals and Drug Treatment
The 5-HT2AR KO and WT littermates were originally generated at Columbia University (US)
on a 129S6/SvEv background [29,75]. Animals were backcrossed over at least ten generations
onto the inbred C57BL/6J line. Male and female 5-HT2AR KO and WTmice were genotyped as
previously described [76]. C57BL/6J male, 9-wk-old mice (Charles River L’Arbresle, France)
were used for the pharmacological and behavioral experiments. Constitutive CB1R KOmice
were bred by backcrossing chimeric animals to the C57BL/6J background and crossing hetero-
zygotes [77]. Mice weighing 20–25 g at the beginning of the experiments were initially housed
four per cage in a temperature-controlled (21 ± 1°C) and humidity-controlled (55 ± 10%) envi-
ronment, where food and water were available ad libitum. All the experiments were performed
during the light phase of a 12 h light/dark cycle (lights on at 8 a.m. and off at 8 p.m.), except for
the WIN 55,212–2 self-administration experiment that was conducted in the dark phase of the
cycle. The CB1R ligands THC (Pharm GmbH, Frankfurt, Germany) and rimonabant (Sanofi-
Aventis Recherche, Montpellier, France) were diluted in 5% ethanol, 5% Cremophor-EL
(Sigma-Aldrich), and 90% saline. WIN 55,212–2 (Sigma-Aldrich) was dissolved in one drop of
Tween 80 (Sigma-Aldrich) and diluted in physiological saline. For the self-administration
experiment, WIN 55,212–2 was administered by intravenous route at 12.5 μg/kg/infusion. The
5-HT2AR antagonist, MDL 100,907 (Sigma-Aldrich), was dissolved in saline solution using a
drop of Tween 80. Except for WIN 55,212–2, all compounds were administered intraperitone-
ally (IP) at a volume of 10 ml/kg.
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Behavioral Experiments
In mice, cannabinoids produce the so-called ‘‘tetrad model” of cannabimimetic activity in the
same dose range and within the same time frame, consisting of hypolocomotion, hypothermia,
antinociception, and catalepsy. Accordingly, we tested the hypolocomotor, hypothermic, and
analgesic effects of THC using a complete dose response, as published in previous studies [78].
For memory deficits induced by THC in mice, previous data from our laboratory [79] have
revealed significant effects in the object discrimination test only with 3 and 10 mg/kg of THC,
which were both tested in the present study. For anxiety-like behavior, it has been shown that
THC produces biphasic effects, with lower and higher doses inducing anxiolytic- and anxio-
genic-like responses, respectively [3,7]. Accordingly, we measured the anxiolytic-like effect of
THC, as well as the consequent increase in social interaction observed, using a low dose
(0.3 mg/kg), and the anxiogenic-like response using a high dose (3 mg/kg). The different
behavioral effects produced by specific doses of THC suggest that a different level of receptor
occupancy is required for each behavioral response [80].
Determination of Locomotor Activity, Social Interaction, Body
Temperature, and Analgesia in Mice
Locomotor responses to acute administration of THC were evaluated by using individual loco-
motor activity boxes (9 x 20 x 11 cm; Pessac, France) provided with two lines of photocells in a
low-luminosity environment (20–25 lux). Mice were placed in the boxes for 45 min (15 min
after THC [0.3, 1, 3, and 10 mg/kg] or vehicle administration), and total horizontal activity was
analyzed. The social interaction test was performed in an open field (40 x 40 cm) in which
mice were habituated for 2 consecutive d in order to maximize the duration of interactions.
Next, animals were treated with THC (0.3 mg/kg) or vehicle, and 30 min after the injection, a
previously established pair of mice (same strain and size and unfamiliar with each other) was
placed into the arena for 10 min. The social interaction test was performed as previously
described [81]. Total time spent in active social interactions (defined as sniffing, fighting, chas-
ing, grooming, or crawling under and over each other) was scored from a recorded video. Data
were expressed as the amount of interaction time per couple. Body temperature was measured
before (basal) and 60 min after THC (1, 3, and 10 mg/kg) or vehicle administration using a
lubricated thermo-coupled flexible probe (Panlab, Madrid, Spain) placed into the rectum for
10 s. Data were expressed as change in temperature from basal recording. Antinociceptive
effects were evaluated using the tail-immersion and hot-plate tests. The tail-immersion test
measures spinal pain responses, which are modulated by descending influences from the brain
stem, cerebellum, basal ganglia, and cerebral cortices. All of these structures comprise CB1R
that play an important role in pain responses [82,83]. The hot-plate test measures supraspinal
antinociception, and direct evidence for supraspinal sites of cannabinoid analgesic action has
been provided (see Palazzo et al., 2010, for review [83]). Sixty minutes after the injection of
THC (1, 3, and 10 mg/kg) or vehicle, the tail-immersion test was carried out, as previously
described [84]. The water temperature was maintained at 50 ± 0.5°C using a thermo-regulated
water-circulating pump (Clifton, North Somerset, United Kingdom). The latency to a rapid tail
flick was registered, and in its absence a 10-s cutoff was used to prevent tissue damage. Subse-
quently, the hot-plate test was performed, as previously reported [85], 90 min after THC (1, 3,
and 10 mg/kg) or vehicle injection. The surface of the plate was kept at 50 ± 0.1°C (Columbus
Instruments, Columbus, Ohio, US), and the nociceptive threshold was evaluated by measuring
licking and jumping responses. A 5-min cutoff was determined to avoid tissue damage. For
both nociceptive models, data were expressed as a percentage of the cutoff latency.
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Determination of the Reinforcing Properties of WIN 55,212–2
Mice were anesthetized with a mixture of ketamine/xylazine (5:1; 0.10 ml/10 g, IP) and
implanted with indwelling intravenous Silastic catheters on their right jugular vein as previ-
ously described [86]. After surgery, animals were individually housed and allowed to recover
for 4 d before initiation of self-administration sessions. The operant model was performed, as
previously described [36], in mouse operant chambers (Med Associates, Georgia, Vermont,
US) equipped with two nose-pokes, one randomly selected as the active and the other as the
inactive nose-poke. Two-hour daily self-administration sessions were conducted consecutively
for 12 d. Animals were injected systemically with WIN 55,212–2 in the home cage 24 h before
the first self-administration session in order to avoid initial aversive effects. Mice were trained
under a fixed ratio 1 (FR1) schedule of reinforcement with a 10-s time-out. Drug self-adminis-
tration sessions started with a priming injection of the drug, and drug infusion delivery was sig-
naled by the stimulus light together with the pump noise (environmental cues). During the
10-s time-out period, responding on the active hole did not trigger the cue light, and no reward
was provided. Each daily session terminated after the delivery of 50 reinforcers or after 2 h,
whichever occurred first. Animals needed to achieve the following criteria during three conse-
cutive sessions for the acquisition of self-administration behavior: (1) stable responding on the
active hole with<20% deviation from the mean of the total number of reinforcers earned (80%
stability); (2) at least 75% responding on the active hole versus the inactive hole (discrimina-
tion); and (3) a minimum of eight reinforcers per session. At the end of the self-administration
experiment, the patency of the intravenous catheters was evaluated by an infusion of thiopental
sodium (0.05 ml at 5 mg/ml) (Braun Medical) through the catheter. Mice that did not show
prominent signs of anesthesia within 3 s of the infusion were discarded from the experiment.
THC-InducedWithdrawal Syndrome Evaluation
Mice were chronically treated with THC (20 mg/kg) or vehicle (twice daily during 5 d intraper-
itoneally) and received an additional THC (20 mg/kg) or vehicle injection on day 6. Four hours
later, the animals were placed in a circular clear plastic observation area (30 cm in diameter
and 50 cm in height) for a 15-min period of habituation. Animals were observed for an addi-
tional period of 15 min, followed by the administration of rimonabant (10 mg/kg). Somatic
signs of withdrawal were evaluated 15 min before and 45 min after rimonabant challenge. The
number of wet-dog shakes, front-paw tremors, writhings, and sniffings were counted. More-
over, body tremor, ptosis, teeth chattering, genital licks, hunched posture, and piloerection
were scored 1 for appearance or 0 for nonappearance within each 5-min time period. The loco-
motor activity was rated 0, 1, or 2 (0 for inactivity, 1 for low activity, and 2 for normal activity)
over 5-min periods. A global withdrawal score was calculated for each animal by giving each
individual sign a relative weight, as previously reported [87].
Memory Impairments Measurements
The novel object recognition task was performed in a V-maze, as previously described [79]. On
the first day, animals were habituated to the maze for 10 min. On the second day, two identical
objects in the maze were presented to the animals for 10 min. Immediately after this training
period, different doses of THC (3 and 10 mg/kg), which have been reported to produce
amnesic-like effects [79], or vehicle were administered to the animals. On the third day, one of
the familiar objects was replaced with a novel object, and the time spent exploring both objects
was measured. A discrimination index (DI) was calculated as the difference between the times
spent exploring either the novel or familiar object divided by the total amount of exploration.
DI values above 0.3 were considered to reflect memory retention for the familiar object.
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Anxiety-like Behavior Determination
Anxiety-like behavior was evaluated using the elevated plus maze (EPM), as previously
described [88], in a black plastic apparatus with four arms extended from a central platform
forming a plus sign. Two opposite arms were delimited by vertical walls (closed arms), whereas
the other two opposite arms had unprotected edges (open arms). The maze was elevated 50 cm
above the floor and received indirect illumination (70–75 lux in the open arms). A 5-min
observation trial was started by placing a mouse on the central platform of the maze with its
head facing towards an open arm. The time spent in open and closed arms as well as the num-
ber of entrances was recorded. An arm visit was counted when the mouse moved both front
paws into the arm. Data are represented as percentage of time spent in the open arms with
respect to the total amount of time spent in the open and closed arms. To test the effect of the
THC as anxiolytic, the elevated plus maze test was performed 30 min after the administration
of 0.3 mg/kg of THC or vehicle, a dose known to induce a decrease in anxiety-like behavior [7].
To test the anxiogenic effect of THC, the elevated plus maze test was performed 5 h after the
administration of a dose of 3 mg/kg or vehicle to the animals.
Electrophysiological Recordings
Immediately after removal from the skull, mouse brains were immersed in an ice-cold artificial
cerebrospinal fluid (aCSF composed of NaCl 126 mM, KCl 3.5 mM, NaH2PO4 1.2 mM, MgCl2
1.3 mM, CaCl2 2.0 mM, NaHCO3 25 mM, and D-glucose 11 mM) continuously bubbled with
carbogen (95% O2/5% CO2) to maintain pH value at 7.3. Tissue containing the DR nucleus was
cut into sections (400 μm thick) in the same ice-cold aCSF using a vibratome. Slices were
immediately immersed in oxygenated aCSF and maintained at room temperature (22°C). A
single slice was then placed on a nylon mesh in the recording chamber, where it was completely
submerged and continuously superfused with oxygenated aCSF (36°C) at a constant flow rate
of 2–3 mL/min. Glass microelectrodes filled with 2M NaCl (12–15 MO) were used to record
the firing activity of DR serotonergic neurons. Neuronal firing was evoked in the otherwise
silent neurons by adding the α1-adrenoceptor agonist phenylephrine (3 μM) into the superfus-
ing aCSF [89] and according to previously described criteria [90]; cells were identified as 5-HT
neurons. Individual action potentials were amplified by a high-input impedance amplifier (VF
180, BioLogic, Claix, France) and displayed in an oscilloscope connected to an electronic rate-
meter, an A/D converter, and a personal computer [91]. The integrated neuronal firing rate
was recorded and analyzed in consecutive 10-s samples. Baseline neuronal activity was
recorded 5 min before perfusing the brain slices with the different concentrations of THC.
Because complete exchange of fluids occurred within 2 min following the arrival of a new solu-
tion into the chamber, the duration of each drug application was 3 min. The effects of THC
perfusion were evaluated by comparing the mean discharge frequency during the 2 min prior
to its application with that recorded at the peak action of the drug. After recovering the firing,
neurons were perfused with 5-HT1A receptor agonist ipsapirone (30 nM) to confirm that neu-
rons were in fact 5-HT neurons. Data are expressed as percentage of the baseline firing
rate ± SEM.
Stereotaxic Surgery, Intracerebroventricular (ICV) Infusion of Peptides,
and Behavioral Experiments
Animals were anaesthetized with a ketamine/xylazine mixture (5:1; 0.10 ml/10 g, IP) and
placed in a stereotaxic apparatus (KOPF Instruments, Tujunga, California). Unilateral cannu-
lae (26 gauge, 8 mm length) were implanted in the right lateral ventricle (AP, -0.2 mm; ML,
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±1.0 mm; DV, -2.3 mm from bregma) [92] and then fixed to the skull with dental cement.
Mice were housed individually and allowed 3 d of postoperative recovery before experiments
began. The ICV injection procedure of interference peptides (TM5, TM6, or TM7) (0.2 μg/2μl)
or vehicle was performed at a constant rate of 1 μl/min by using a microinfusion pump (Har-
vard Apparatus) attached to a 10-μl Hamilton microsyringe (Hamilton, Reno, Nevada) and
connected to the ICV cannula through a polyethylene tube (PE-10, Plastics One, Roanoke, Vir-
ginia). The tube was removed from the cannula 1 min after the infusion in order to prevent
drug reflux. After completion of the experiments, 0.05% methylene blue solution was infused
to check the correct position of the cannulae, and data from mice with incorrect placements
were discarded. All behavioral tests were performed in the same animals, and 3-d wash-out
periods were allowed between tests and ICV infusions. Memory impairments were determined
first in the V-Maze. ICV infusions were performed immediately after the training phase and
30 min before THC (3.0 mg/kg IP) or vehicle administration. In order to assure the disruption
of the heteromer during the entire time course of THC effects, ICV peptide infusions were
repeated 3 h after the first infusion. In concordance with the previous experiment, V-Maze test
was performed 24 h after training. Second, anxiety-like responses were carried out in the EPM.
ICV infusions were performed 30 min before THC (0.3 mg/kg IP) or vehicle administration,
and plus maze observation was conducted 30 min later, in the appropriate conditions to evalu-
ate THC-induced anxiolytic effects. Locomotor activity, body temperature, and analgesia were
determined last. Here, ICV infusions were performed 30 min before THC (10 mg/kg IP) or
vehicle administration. Fifteen minutes later, animals were placed in locomotor activity boxes
for a total of 45 min. Body temperature and tail immersion were performed 60 min after THC
or vehicle administration.
CB1R Expression and Endocannabinoid Quantification
Mouse brain samples were dissected, weighted, and immediately frozen at -80°C and kept
under these conditions until used. Frozen hippocampal, striatal, cortical, and nucleus accum-
bens tissues were homogenized using a glass homogenizer in 30 volumes of lysis buffer (50
mM Tris-HCl pH 7.4, 150 mMNaCl, 10% glycerol, 1 mM EDTA, 1 μg/mL aprotinin, 1 μg/mL
leupeptine, 1 μg/mL pepstatin, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovana-
date, 100 mM sodium fluoride, 5 mM sodium pyrophosphate, and 40 mM beta-glycerolpho-
sphate) plus 1% Triton X-100. After 10 min incubation at 4°C, samples were centrifuged at
16,000 g for 20 min to remove insoluble debris. Supernatants were collected, and their protein
contents were determined by DC-micro plate assay (Bio-Rad, Madrid, Spain), following manu-
facturer’s instructions. Samples with equal amounts of protein (20 μg per lane) were mixed
with denaturing Laemmli loading buffer and separated in a 10% acrylamide gel before electro-
phoretic transfer onto Immobilon PVDF membrane (Millipore, Darmstadt, Germany). Mem-
branes were blocked for 1 h at room temperature in Tris buffered saline (TBS) with 0.1%
Tween-20 (TBS-T) and 5% nonfat milk. Subsequently, membranes were incubated for 2 h with
antibodies against CB1R (1:1,000 in TBS-T) (Frontier Science, Ishikari, Japan) and glyceralde-
hyde-3-phospate dehydrogenase (GAPDH) (1:5,000 in TBS-T with 5% nonfat milk) (Santa
Cruz Biotechnology, Santa Cruz, California) as a loading control. Secondary HRP-conjugated
antibodies were incubated for 1 h and visualized by enhanced chemiluminescence detection
(Luminata Forte, Millipore). The optical density of the relevant immunoreactive band was
quantified after acquisition on a Chemi-Doc XRS System (Bio-Rad) by The Quantity One soft-
ware. Each sample was measured in two independent gels, and the values for CB1R were nor-
malized to the detection of GAPDH in the same samples and expressed as a percentage of the
controls. Endocannabinoids were quantified as previously described [93]. Animals were treated
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with specific inhibitors of the endocannabinoid metabolizing enzymes fatty acid amide hydro-
lase, URB597 (Biomol-International, Exeter, UK), and monoacylglycerol lipase, JZL184 (Cay-
man Chemical, Ann Arbor, Michigan). URB597 was injected 1 h before brain extractions,
whereas JZL184 was injected 2 h before brain extractions. Both compounds were dissolved in
dimethyl sulfoxide (DMSO) (Scharlau Chemie, Barcelona, Spain) and injected IP in a volume
of 2 ml/kg. Brain samples were immediately frozen at -80°C and kept under this condition
until used. Brain tissue was homogenated with a glass homogenizer in 1 ml 0.02% TFA (pH
3.0) and aliquots of 150 or 20 μl were used for anandamide (AEA) analysis or 2-AG analysis,
respectively. Extracts (20 μl) were injected into the liquid chromatography—mass spectrome-
try (LC-MS-MS) system. An Agilent 6410 triple quadrupole (Agilent Technologies, Wilming-
ton, Delaware) equipped with a 1200 series binary pump, a column oven, and a cooled
autosampler (4°C) were used. The chromatographic separation was carried out with a Zorbax
80Å StableBond C8 column (2.1 x 100 mm, 1.8 μm particle size) maintained at 40°C with a
mobile phase flow rate of 0.4 ml/min. The composition of the mobile phase was A: 0.1% (v/v)
FA in water and B: 0.1% (v/v) FA in acetonitrile. The initial conditions were 40% B. The gradi-
ent was increased linearly to 100% B over 4 min, maintained at 100% B for 4 min, and
returned to the initial conditions for a further 5.5 min, with a total run time of 13.5 min. The
tandem quadrupole mass spectrometer operated on the positive electrospray mode. Desolva-
tion gas temperature of 350°C and a gas flow rate of 10 l/min were used. The pressure of the
nebulizer was set at 40 psi and the capillary voltage at 4,000 V. The detection was done by the
multiple-reaction monitoring mode, the fragmentor was set at 135 V, and the collision ener-
gies were optimized at 12 V for all analytes. The following precursors to product ion transi-
tions were used: m/z 348!62 for AEA, m/z 352!66 for AEA-d4, 379.2!287 for 2- AG, and
m/z 384!287 for 2-AG-d5. The quantification was done by isotope dilution based on the
deuterated analogues response. The limit of detection on column was 8 pg for AEA and 200
pg for 2-AG.
Expression Vectors
All human cDNA used were cloned into the pcDNA3.1 vector with geneticin resistance. The
cDNA for 5-HT2AR was also cloned in a p-CMV hygro destination vector with hygromycin
resistance. Sequences encoding amino acid residues 1–155 and 156–238 of YFP Venus protein
were subcloned in the pcDNA3.1 vector to obtain the YFP Venus hemi-truncated proteins.
The cDNAs for 5-HT2AR and dopamine D1R were amplified without their stop codons using
sense and antisense primers harboring unique EcoRI and Xhol or EcoRI and BamHI sites,
respectively. The cDNAs for CB1R and adenosine A1R were amplified without their stop
codons using sense and antisense primers harboring unique EcoRI and KpnI. The amplified
fragments were subcloned to be in-frame with restriction sites of pcDNA3.1RLuc (pRLuc-N1
PerkinElmer, Wellesley, Massachusetts), pEYFP-N1 (enhanced yellow variant of GFP, Clon-
tech, Heidelberg, Germany), pcDNA3.1-cVenus, or pcDNA3.1-nVenus vectors to give the
plasmids that express proteins fused to RLuc, YFP, or hemi-YFP Venus on the C-terminal end
(5-HT2AR-RLuc, 5-HT2AR-cYFP, D1R-RLuc, D1R-cYFP, CB1R-YFP, CB1R-nYFP, A1R-nYFP,
or A1R-YFP). Human β-arrestin II-Rluc6, cloned in the pcDNA3.1 RLuc6 vector (pRLuc-N1
PerkinElmer, Wellesley, Massachusetts) was generously given by Dr. Marian Castro from San-
tiago de Compostela University, Spain. Expression of constructs was tested by confocal micros-
copy and the receptor fusion protein functionality by ERK1/2 phosphorylation, as described
previously [94–96].
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Cell Culture and Transient Transfection
Human embryonic kidney (HEK-293T) cells obtained from ATCC and HEK-293T cell clones
were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) supplemented with 2
mM L-glutamine, 100 μg/ml sodium pyruvate, 100 U/ml penicillin/streptomycin, MEM Non-
Essential Amino Acids Solution (1/100), and 5% (v/v) heat inactivated fetal bovine serum
(FBS) (all supplements were from Invitrogen, Paisley, Scotland, UK). As cells expressing CB1R,
we used a HEK-293T-CB1R clone obtained by transfecting HEK-293T cells with CB1R cDNA,
selected and cultured also in the presence of 200 μg/ml zeocin. To obtain cells expressing
5-HT2AR, HEK-293T cells were transiently transfected. HEK-293T cells expressing CB1R and
5-HT2AR were developed from a HEK-293T-CB1R clone by transient transfection of the
cDNA corresponding to the 5-HT2AR cloned in a p-CMV hygro destination vector and
selected in the presence of 200 μg/ml zeocin and 300 μg/ml hygromycin for 3 d. Alternatively,
HEK-293T cells were transiently cotransfected with cDNA corresponding to both 5-HT2AR
and CB1R to perform the experiments showed in Fig 4D. Cells growing in 6-well dishes were
transiently transfected with the corresponding protein cDNA by the PEI (PolyEthylenImine,
Sigma) method. Cells were incubated (4 h) with the corresponding cDNA together with PEI
(5.47 mM in nitrogen residues) and 150 mMNaCl in a serum-starved medium. After 4 h, the
medium was changed to a fresh complete culture medium. Forty-eight hours after transfection,
cells were washed twice in quick succession in HBSS with 10 mM glucose, detached, and resus-
pended in the same buffer. Cells were maintained at 37°C in an atmosphere of 5% CO2. To
control the cell number, sample protein concentration was determined using a Bradford assay
kit (Bio-Rad, Munich, Germany) using bovine serum albumin dilutions as standards.
Fluorescence Complementation Assays
HEK-293T were transiently transfected with the cDNA encoding for CB1R or A1R fused to the
YFP Venus N-terminal fragment (n-YFP) and 5-HT2AR or D1R fused to the YFP Venus C-ter-
minal fragment (c-YFP). After 48 h, cells were treated or not with the indicated TAT-peptides
(4 μM) for 4 h at 37°C. To quantify the complemented YFP Venus expression, cells (20 μg pro-
tein) were distributed into 96-well microplates (black plates with a transparent bottom, Por-
vair, King’s Lynn, UK), and fluorescence emission at 530 nm was recorded in a Fluo Star
Optima Fluorimeter (BMG Labtechnologies, Offenburg, Germany) equipped with a high-
energy xenon flash lamp, using a 10-nm bandwidth excitation filter at 400 nm reading. Protein
fluorescence was determined as fluorescence of the sample minus the fluorescence of untrans-
fected cells (basal). Cells expressing 5-HT2AR-cVenus and nVenus or CB1R-nVenus and cVe-
nus showed similar fluorescence levels to nontransfected cells.
BRET Assays
HEK-293T cells were transiently cotransfected with a constant amount of expression vectors
encoding for proteins fused to RLuc and with increasing amounts of the expression vectors cor-
responding to proteins fused to YFP (see figure legends). To quantify protein-YFP expression,
cells (20 μg protein, around 4,000 cells/well) were distributed in 96-well microplates (black
plates with a transparent bottom), and fluorescence was read in a Fluo Star Optima Fluorimeter
(BMG Labtechnologies, Offenburg, Germany) equipped with a high-energy xenon flash lamp,
using a 10-nm bandwidth excitation filter at 400 nm reading. Fluorescence expression was
determined as fluorescence of the sample minus the fluorescence of cells only expressing the
BRET donor. For BRET measurements, the equivalent of 20 μg of cell suspension was distrib-
uted into 96-well microplates (Corning 3600, white plates; Sigma) and 5 μM coelenterazine H
(Molecular Probes, Eugene, OR) was added. The readings were taken 1 min later using a
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Mithras LB 940. The integration of the signals detected in the short-wavelength filter at 485
nm (440–500 nm), and the long-wavelength filter at 530 nm (510–590 nm) was recorded. To
quantify protein-RLuc expression luminescence, readings were also performed 10 min after
adding 5 μM coelenterazine H. Fluorescence and luminescence of each sample were measured
before every experiment to confirm similar donor expressions (approximately 100,000 biolu-
minescence units) while monitoring the increase in acceptor expression (1,000 to 40,000 fluo-
rescence units). The net BRET is defined as [(long-wavelength emission) / (short-wavelength
emission)]–Cf, where Cf corresponds to [(long-wavelength emission) / (short-wavelength
emission)] for the donor construct expressed alone in the same experiment. BRET is expressed
as mBU (net BRET x 1,000). Data were fitted to a nonlinear regression equation, assuming a
single-phase saturation curve with GraphPad Prism software (San Diego, California, US).
Immunodetection Assays
For immunocytochemistry, HEK-293T cells stably expressing CB1R were grown on glass cov-
erslips and were transiently transfected with the corresponding cDNA. After 48 h of transfec-
tion, cells were fixed in 4% paraformaldehyde for 15 min and washed with phosphate-buffered
saline (PBS) containing 20 mM glycine to quench the aldehyde groups. After permeabilization
with PBS-glycine containing 0.05% Triton X-100 for 5 min, cells were incubated 1 h at room
temperature with PBS containing 1% bovine serum albumin and were labeled overnight with
the corresponding primary antibody: guinea pig anti-CB1R (Frontier Science, Ishikari, Japan)
or rabbit anti-CB1R antibody (Thermo Scientific, Fremont, California), rabbit anti-5-HT2AR
antibody (Neuromics, Edina, Minnesota), mouse anti-transferrin antibody (Abcam, Cam-
bridge, UK) or guinea pig anti-D1R antibody (Frontier Science, Ishikari, Japan); washed, and
stained 2 h with the secondary antibody: chicken anti-rabbit (1:200, Alexa Fluor 594, Invitro-
gen), goat anti-guinea pig (1:200, Alexa Fluor 488, Invitrogen), or goat anti-mouse (1:200,
Alexa Fluor 488, Invitrogen). Samples were rinsed several times and mounted with Mowiol
medium (30%Mowiol, Calbiochem, Darmstadt, Germany) and observed using a Leica SP2
confocal microscope (Leica Microsystems, Mannheim, Germany).
Dynamic Mass Redistribution (DMR) Assays
The global cell signaling profile was measured using an EnSpire Multimode Plate Reader (Per-
kinElmer, Waltham, Massachusetts, US). This label-free approach uses refractive waveguide
grating optical biosensors, integrated into 384-well microplates. Changes in local optical den-
sity are measured in a detection zone up to 150 nm above the surface of the sensor. Cellular
mass movements induced upon receptor activation are detected by illuminating the underside
of the biosensor with polychromatic light and measured as changes in the wavelength of the
reflected monochromatic light. These changes are a function of the refraction index. The mag-
nitude of this wavelength shift (in picometers) is directly proportional to the amount of DMR.
Briefly, 24 h before the assay, cells were seeded at a density of 10,000 cells per well in 384-well
sensor microplates with 30 μl growth medium and cultured for 24 h (37°C, 5% CO2) to obtain
70%–80% confluent monolayers. Previous to the assay, cells were washed twice with assay
buffer (HBSS with 20 mMHEPES, pH 7.15) and incubated 2 h in 30 μl per well of assay-buffer
with 0.1% DMSO in the reader at 24°C. Hereafter, the sensor plate was scanned, and a baseline
optical signature was recorded before adding 10 μl of test compound dissolved in assay buffer
containing 0.1% DMSO. Then, DMR responses were monitored for at least 5,000 s. Kinetic
results were analyzed using EnSpire Workstation Software v 4.10.
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Brain Slices Preparation
Mice brains were rapidly removed and placed in ice-cold oxygenated (95%O2/5%CO2) Krebs-
HCO3- buffer (containing [in mM]: 124 NaCl, 4 KCl, 1.25 KH2PO4, 1.5 MgCl2, 1.5 CaCl2,
10 glucose, and 26 NaHCO3, pH 7.4). The brains were sliced coronally at 4°C. Slices containing
cortex, striatum, nucleus accumbens, or hippocampus (500 μm thick) were kept at 4°C in this
Krebs-HCO3-buffer during the dissection and were transferred into an incubation tube con-
taining 1 ml of ice-cold Krebs-HCO3-buffer. The temperature was raised to 23°C, and after
30 min the medium was replaced by 2 ml of fresh Krebs-HCO3-buffer (23°C). The slices were
incubated under constant oxygenation (O2/CO2: 95%/5%) at 30°C for 4–5 h in an Eppendorf
Thermomixer (5 Prime, Boulder, Colorado, US). The media was replaced by 200 μl of fresh
Krebs-HCO3-buffer and incubated for 30 min before the addition of any agent. Slices were
treated or not with the indicated ligand for the indicated time. After the indicated incubation
period, the solution was discarded, and slices were frozen on dry ice and stored at -80°C.
Determination of Phospho-ERK 1/2 and Phospho-Akt/PKB in Cells and
in Brain Tissue
Transfected HEK-293T cells were cultured in serum-free medium for 16 h before the addition
of any compounds. Brain slices were isolated and prepared as indicated above. Cells or slices
were either treated or not with the indicated ligands for the times noted, rinsed with ice-cold
PBS, and lysed by the addition of 500 μl of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, 50
mMNaF, 150 mMNaCl, 45 mM glycerophosphate, 1% Triton X- 100, 20 μM phenyl-arsine
oxide, 0.4 mM NaVO4, and protease inhibitor mixture). Cellular debris was removed by centri-
fugation at 13,000 g for 5 min at 4°C, and the amount of protein was quantified by the bicinch-
oninic acid method using bovine serum albumin dilutions as standard. Equivalent amounts of
protein (10 μg) were separated by electrophoresis on a denaturing 10% SDS-polyacrylamide
gel and transferred onto PVDF-fluorescence membranes. The membranes were blocked using
Odyssey blocking buffer (LI-COR Biosciences), and the membrane was incubated and rocked
for 90 min. Membranes were probed with a mouse anti-phospho- ERK1/2 antibody (1:2,500;
Sigma, Steinheim, Germany), a rabbit anti-phospho-Ser473-Akt antibody (1/2,500, SAB Sig-
nalway Antibody, Pearland, Texas, US), and a rabbit anti-ERK1/2 antibody that recognizes
both phosphorylated and nonphosphorylated ERK1/2 (1:40,000; Sigma) simultaneously for
2–3 h. Bands were visualized by the addition of both IRDye 800 (anti-mouse) antibody
(1:10,000; Sigma) and IRDye 680 (anti-rabbit) antibody (1:10,000; Sigma) for 1 h. Following
incubation, the membranes were washed and scanned by the Odyssey infrared scanner
(LI-COR Biosciences). Band densities were measured using the scanner software and then
transferred to Excel (Microsoft). Phosphorylated ERK1/2 isoforms or phosphorylated Akt lev-
els were normalized for differences in loading using protein band intensities for total ERK.
In Situ PLAs in Cells and in Brain Tissue
For proximity ligation assays, mouse brains were fixed by immersion with 4% paraformalde-
hyde solution for 36 h at 4°C. Samples were then washed in 50 mM Tris-HCl, 0.9% NaCl pH
7.8 buffer (TBS), cryopreserved in a 30% sucrose solution for 48 h at 4°C, and stored at -20°C
until sectioning. 30-μm-thick slices were cut sagittally on a freezing cryostat (Leica Jung CM-
3000) and mounted on slide glass. Brain slices were thawed at 4°C, washed in TBS, permeabi-
lized with TBS containing 0.01% Triton X-100 for 10 min, and successively washed with TBS.
Cells stably expressing CB1R and transfected with the corresponding cDNA were grown on
glass coverslips and were fixed in 4% paraformaldehyde for 15 min, washed with PBS
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containing 20 mM glycine, permeabilized with the same buffer containing 0.05% Triton X-100,
and successively washed with PBS. Heteromers were detected using the Duolink II in situ PLA
detection Kit (OLink; Bioscience, Uppsala, Sweden) and following the instructions of the sup-
plier. To detect CB1R-5-HT2AR heteromers, a mixture of equal amounts of rabbit anti-CB1R
antibody (Thermo Scientific, Fremont, California) directly linked to a plus PLA probe and rab-
bit anti-5-HT2AR antibody (Neuromics, Edina, MN) directly linked to a minus PLA probe was
used. PLA probe was linked to the antibodies following the instructions of the supplier. To
detect CB1R-transferrin receptor or CB1R-D1R heteromers, a mixture of equal amounts of rab-
bit anti-CB1R antibody and mouse anti-transferrin antibody (Abcam, Cambridge, UK) or
guinea pig anti-D1R antibody (Frontier Institute, Ishikari, Hokkaido, Japan) were used and
incubated with anti-rabbit plus and anti-mouse minus PLA probes or anti-rabbit plus and
anti-guinea pig minus PLA probes, respectively. Cells and slices were mounted using the
mounting medium with DAPI. The samples were observed in a Leica SP2 confocal microscope
(Leica Microsystems, Mannheim, Germany) equipped with an apochromatic 63X oil-immer-
sion objective (N.A. 1.4), and a 405 nm and a 561 nm laser line. For each field of view, a stack
of two channels (one per staining) and 9 to 15 Z stacks with a step size of 1 μm were acquired.
Images were opened and processed with Image J confocal. After image processing, the red
channel was depicted in green color to facilitate detection on the blue-stained nucleus and to
maintain the color intensity constant for all images. In tissue, a quantification of cells contain-
ing one or more green spots versus total cells (blue nucleus) was determined considering a total
of 1,500–3,000 cells from 4–12 different fields within each region from three different animals.
In cells, the ratio r (number of red spots/number of cells containing spots) was determined con-
sidering a total of 1,500–3,000 cells from 8–12 different fields. In both cases, the ImageJ confo-
cal program using the Fiji package (http://pacific.mpi-cbg.de/) was used. Nuclei and green
spots were counted on the maximum projections of each image stack. After getting the projec-
tion, each channel was processed individually. The nuclei were segmented by filtering with a
median filter, subtracting the background, enhancing the contrast with the contrast limited
adaptive histogram equalization (CLAHE) plug-in, and finally applying a threshold to obtain
the binary image and the regions of interest (ROIs) around each nucleus. Green spot images
were also filtered and thresholded to obtain the binary images. Green spots were counted in
each of the ROIs obtained in the nuclei images.
cAMP Production and Arrestin Recruitment
For cAMP production, homogeneous time-resolved fluorescence energy transfer (HTRF)
assays were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, Massachu-
setts, US), based on competitive displacement of a europium chelate-labelled cAMP tracer
bound to a specific antibody conjugated to acceptor beads. We first established the optimal cell
density for an appropriate fluorescent signal. This was done by measuring the TR-FRET signal
determined as a function of forskolin concentration using different cell densities. The forskolin
dose-response curves were related to the cAMP standard curve in order to establish which cell
density provides a response that covers most of the dynamic range of cAMP standard curve.
Cells (1,000 cells/well) growing in medium containing 50 μM zardeverine were pretreated with
the antagonists or the corresponding vehicle in white ProxiPlate 384-well microplates (Perki-
nElmer) at 25°C for 20 min and stimulated with agonists for 15 min before adding 0.5 μM for-
skolin or vehicle and incubating for an additional 15-min period. Fluorescence at 665 nm was
analyzed on a PHERAstar Flagship microplate reader equipped with an HTRF optical module
(BMG Lab technologies, Offenburg, Germany). Arrestin recruitment was determined using
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BRET experiments as described above in HEK-293T expressing β-arrestin II-Rluc, 5-HT2AR--
YFP and CB1R after the indicated treatment with ligands.
Calcium Signalling
To determine calcium release, cells stably expressing CB1R were transfected with the cDNA for
5-HT2AR and 4 μg of GCaMP6 calcium sensor [97] using lipofectamine. 48 h after transfection,
cells were incubated (0.2 mg of protein/ml in 96-well black, clear bottom microtiter plates)
with Mg+2-free Locke’s buffer pH 7.4 (154 mMNaCl, 5.6 mM KCl, 3.6 mM NaHCO3, 2.3 mM
CaCl2, 5.6 mM glucose, and 5 mMHEPES) supplemented with 10 μM glycine. Then, receptor
ligands were added as indicated. Fluorescence emission intensity of GCaMP6 was recorded at
515 nm upon excitation at 488 nm on an EnSpire Multimode Plate Reader (PerkinElmer, Bos-
ton, Massachusetts, US) for 335 s every 15 s and 100 flashes per well.
Statistical Analyses
The behavioral data are presented as mean + SEM and were analyzed using one-, two-, or
three-way ANOVA when appropriate with genotype (WT and 5-HT2AR KOmice) and treat-
ment (vehicle and THC) or pretreatment (vehicle and MDL 100,907) and treatment (vehicle
and THC) as between-subjects factors, followed by post hoc comparisons when appropriate.
The WIN 55,212–2 self-administration data were analyzed using three-way ANOVA with
genotype (WT and 5-HT2AR KOmice) as between-subjects factor and nose-poke (active and
inactive) and day of session as within-subjects factors. Statistical significance was set at
p< 0.05 level. All tests were two-sided. The in vitro data are represented as mean + SEM and
were analyzed using unpaired Student’s t test or one-way ANOVA followed by Bonferroni
post-hoc tests when appropriate.
Supporting Information
S1 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data for
figure panels Fig 1A–1C, Fig 1E–1I, Fig 2A–2G, Fig 3A–3D, Fig 4A–4B, Fig 4D, Fig 5A–5D,
Fig 5F–5H, Fig 7B–7D, Fig 8B, Fig 9A–9D, Fig 10A–10D, Fig 10F–10I, S1B–S1E Fig, S2A–S2D
Fig, S3A–S3F Fig, S5A–S5H Fig, S6A–S6D Fig, S9 Fig, and S11A–S11J Fig.
(XLSX)
S1 Fig. CB1R protein levels and endocannabinoid quantification in WT and 5-HT2AR KO
mice. In (A) western blots are represented showing the presence of CB1R in the cortex, striatum,
nucleus accumbens, and hippocampus of CB1RWT, but not of KOmice. In (B and C), the per-
centage of CB1R protein with respect to GAPDH was reduced in the hippocampus (B) and cere-
bellum (C) of WT and 5-HT2AR KOmice repeatedly treated with THC, and this effect was
significantly greater in the hippocampus of KO animals, but not in the cerebellum (n = 5–6).
Representative western blot bands are depicted in the lower panels.  p< 0.001 versus vehicle;
# p< 0.05, ## p< 0.01 versus WT animals. In (D and E), the levels of anandamide (D) were sig-
nificantly reduced in 5-HT2AR KOmice as compared toWTmice, while 2-arachidonoylglycerol
(2-AG) levels (E) were similar in both genotypes (n = 7–8).  p< 0.05 versus WT animals. The
statistical analyses used and their corresponding F and p-values are shown in S2 Table.
(TIFF)
S2 Fig. Selectivity of CB1R and 5-HT2AR agonists and antagonists. DMR analysis was per-
formed in HEK-293Tcells expressing CB1R (A and B) or 5-HT2AR (C and D). In (A and C),
cells were stimulated with increasing concentrations of CB1R agonists WIN 55,212–2 (WIN)
or THC (A) or 5-HT2AR agonists DOI or serotonin (C). In (B and D), cells were pretreated for
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20 min with medium, the CB1R antagonist rimonabant (1 μM, RIM), or the 5-HT2AR antago-
nist MDL 100,907 (300 nM, MDL) before stimulation with WIN 55,212–2 (WIN), or DOI. In
all cases, the resulting picometer shifts of reflected light wavelength (pm) were monitored over
time. Each curve is the mean of a representative optical trace experiment carried out in tripli-
cates.
(TIF)
S3 Fig. CB1R are associated to a Gi protein and 5-HT2AR are associated to a Gq protein
when expressed alone.HEK-293T cells expressing CB1R (A and B) or 5-HT2AR (C–F) were
used. Cells were not treated (control) or treated overnight with 10 ng/ml pertussis toxin (PTX,
A–D), treated 1 h (B and D) or overnight (A and C) with 100 ng/ml cholera toxin (CTX), or
treated for 30 min with 1 μM of the Gq protein inhibitor YM-254890 (B–E). In (A, C, and E),
the dynamic mass redistribution analysis was performed in (A) control cells (red line), cells
treated with PTX (green line) or CTX (blue line) stimulated with 50 nMWIN 55,212–2 or (C
and E) control cells (black lines), cells treated with PTX (purple line C) or CTX (yellow line C),
or cells treated with YM-254890 (orange line E), stimulated with 100 nM DOI. The resulting
picometer shifts of reflected light wavelength (pm) were monitored over time. Each curve is the
mean of a representative optical trace experiment carried out in triplicates. In (B and D),
cAMP production was determined after stimulation with 100 nM DOI or 100 nMWIN
55,212–2 (WIN) in the absence or in the presence of 0.5 μM forskolin. Values (cAMP produced
in each condition minus basal stimulation in the absence of forskolin or agonists) represent
mean ± SEM of n = 3–4 and are expressed as the percentage of the forskolin-treated cells in
control conditions (120–150 pmols cAMP/106 cells). For cells treated with forskolin, one-way
ANOVA followed by a Dunnett’s multiple comparison post hoc test showed a significant effect
over the forskolin-alone effect in each condition ( p< 0.001). Basal cAMP concentration
was very similar in all conditions. In (F), intracellular calcium release was monitored in
untreated HEK-293T cells expressing 5-HT2AR (black curve) or pretreated with the 5-HT2AR
antagonist MDL 100,907 (300 nM, orange curve) 30 min before stimulation with 100 nM DOI.
Values are mean ± SEM of n = 3.
(TIF)
S4 Fig. Negative controls for proximity ligation assays in transfected cells. PLAs were per-
formed in HEK-293T cells stably expressing CB1R (A) or stably expressing CB1R and trans-
fected with 2 μg cDNA corresponding to dopamine D1 receptors (B). PLA was performed
using anti-CB1R antibody and anti-transferrin receptor antibodies (A) or anti-CB1R antibody
and anti-D1R antibodies (B) as primary antibodies. Confocal immunocytochemistry images
are shown at top in (A and B) showing colocalization (yellow) between CB1R (red) and trans-
ferrin (green) or D1 (green) receptors. In (C), PLA was performed in a 1:1 mixture of cells
only expressing CB1R or 5-HT2AR using anti-CB1R and anti-5-HT2AR antibodies. Confocal
microscopy images (superimposed sections) are shown in which green spots corresponding to
the heteromers are absent in all cases. Cell nuclei were stained with DAPI (blue). Scale
bars = 20 μm
(TIF)
S5 Fig. Time and dose response for agonist-induced signaling in cells expressing CB1R or
5-HT2AR alone. HEK-293Tcells expressing CB1R (A, B, E, and F) or 5-HT2AR (C, D, G, and
H) were stimulated at increasing times (min) with 100 nMWIN 55,212–2 (WIN) (A and E) or
for 5 min with increasing WIN 55,212–2 concentrations (μM) (B and F) or were stimulated for
increasing times (min) with 100 nM DOI (C and G) or for 5 min with increasing DOI concen-
trations (μM) (D and H), and quantification of phosphorylated ERK 1/2 (A, B, C, and D) or
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Akt (E, F, G, and H) was determined by western blot. Values, expressed as percentage of basal
(nonagonist treated cells), were mean ± SEM of n = 3–6.
(TIF)
S6 Fig. Time response of agonist-induced signaling in cells coexpressing CB1R and
5-HT2AR and determination of ligand specificity in cells expressing single receptors. In (A
and B), HEK-293T cells expressing 5-HT2AR and CB1R were stimulated at increasing times
(min) with 100 nMWIN 55,212–2 (WIN), 100 nM DOI, or both. In (C and D), HEK-293Tcells
expressing CB1R (C) or 5-HT2AR (D) were preincubated or not with rimonabant (1 μM, RIM)
or MDL 100,907 (300 nM, MDL) for 15 min and then stimulated for 5 min with WIN 55,212–
2 (100 nM, WIN) or DOI (100 nM). Quantification of phosphorylated ERK 1/2 or Akt was
determined by western blot. Values, expressed as percentage of basal (nonagonist or antagonist
treated cells), were mean ± SEM of n = 3–6. One-way ANOVA followed by Bonferroni post
hoc tests showed a significant ( p< 0.05,  p< 0.001) effect over basal or no significant
effect (p> 0.04) of the antagonist plus agonist treatment over the agonist treatment.
(TIF)
S7 Fig. Dynamic properties of the CB1R-5-HT2AR heteromer. (A) Intracellular view of the
CB1R-5-HT2AR heteromer (blue and green protomers) bound to DOI (green surface) and
rimonabant (red surface), modeled from the crystal structure of the μ-opioid receptor (PDB id
4DKL) [1]. TMs 5 and 6 of rhodopsin (light brown, 1GZM) [2], the β2-adrenergic receptor
(yellow, 2RH1) [3], and the β2-adrenergic receptor in complex with Gs (orange, 3SN6) [4] are
superimposed on the 5-HT2AR. This superimposition shows that the conformational equilib-
rium of GPCRs primarily consists of different conformations of TMs 5 and 6, opening or clos-
ing an intracellular cavity for binding of the G-protein with minimal movement of the other
TMs. Agonists stabilize conformations of TMs 5 and 6 that facilitate the opening of this intra-
cellular cavity (TMs 5 and 6 in orange), whereas inverse agonists (antagonists) stabilize other
conformations of these helices that close this cavity (TMs 5 and 6 in green, light brown, or yel-
low). TMs 5 and 6 of protomer A, in the closed conformations, can interact with TMs 5 and 6
of protomer B (via a four-helix bundle, green and blue TMs 5 and 6) as observed in the crystal
of the μ-opioid receptor. In this assembly, both protomers are locked in the closed conforma-
tion since the opening of TMs 5 and 6 for G-protein binding is not feasible. (B) Many GPCRs
can bind their G-protein in the absence of an agonist, showing basal activity [5]. This suggests
that GPCRs are dynamic proteins that permit rapid small-scale structural fluctuations and pass
through an energy landscape to adopt a number of conformations, ranging from inactive to
active [6]. The transition probability from one state to another depends on the energy differ-
ence between both states and the energy barrier between them. Ligand binding to a monomer
(left panel, adapted from [7]) changes the shape of the energy landscape relative to the unli-
ganded landscape (black line), in such a manner that inverse agonists/antagonists (in red) sta-
bilize inactive conformations (red line), agonists (in green) stabilize intermediate
conformations, and the final formation of the agonist-receptor-G-protein complex stabilizes
active conformations (green line). Based on our findings, we propose that in the case of recep-
tor heteromers (right panel) one of the protomers allosterically modulates the energy landscape
of the interacting receptor. Relative to the unliganded landscape (black line), in which both TM
5 and TM 6 of the receptor (see above) and the TM contacts between protomers are in a
dynamic equilibrium of conformations, antagonist binding stabilizes the inactive conforma-
tions of the receptor (closed cavity) plus the four-helix TM 5 and TM 6 bundle (red line).
Importantly, this energy minimum of the antagonist-bound receptor is more stable in hetero-
mers than in monomers because of the additional formation of the four-helix bundle. These
low free-energy states of the antagonist-bound heteromer (inactive states) impede the
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possibility that agonist binding to the other protomer would reach the energy minima of the
active states (blue line), leading to cross antagonism. Agonist binding to one protomer stabi-
lizes the active conformations of TM 5 and TM 6 (open cavity), TM contacts between proto-
mers that facilitate these active conformations, and the binding of the G-protein to the active
protomer (dark green line). Simultaneous activation of both protomers by their corresponding
agonists leads to energy minima less stable than activation of a single protomer (light green
line), most probably because of a steric clash of the active conformations of TM 5 and TM 6 in
both protomers, which results in a reduction of cell signaling.
(TIF)
S8 Fig. Effects of disrupting peptides on CB1R and 5-HT2AR expression and colocalization.
Immunocytochemistry experiments were performed in cells expressing CB1R and 5-HT2AR
preincubated for 4 h with vehicle (top panels) or with 4 μM of CB1R TM 5, TM 6, or TM 7
interference peptides using guinea pig anti-CB1R (Frontier Science, Ishikari, Japan) and
rabbit anti-5-HT2AR antibody (Neuromics, Edina, Minnesota). Confocal microscopy images
showing colocalization (yellow) between CB1R (green) and 5-HT2AR (red) are shown. Scale
bars = 20 μm.
(TIF)
S9 Fig. Effects of disrupting peptides on CB1R-5-HT2AR heteromerization.HEK-293T cells
transfected with 4 μg of cDNA corresponding to both 5-HT2AR-cYFP and CB1R-nYFP were
treated for 4 h with vehicle or 4 μM of CB1R TM 5, TM 6, or TM 7 interference peptides prior
to the fluorescence determination at 530 nm. One-way ANOVA followed by Bonferroni post
hoc tests showed a significant ( p< 0.05,  p< 0.001) effect over basal fluorescence (1,500–
2,000 fluorescence units in nontransfected cells) or compared to peptide treatment over the
vehicle treatment (## p< 0.01, ### p< 0.001).
(TIF)
S10 Fig. Negative controls for proximity ligation assays in brain slices. PLAs were per-
formed using slices of mouse cortex (somatomotor layers 1, 2, and 3), caudate-putamen (stria-
tum), hippocampus CA3, or nucleus accumbens (NaC) fromWT (A) and 5-HT2AR KO (B)
mice, using anti-CB1R and anti-dopamine D1 receptor antibodies as primary antibodies. Con-
focal microscopy images (superimposed sections) are shown in which green spots correspond-
ing to the heteromers are absent in all panels. In all cases, cell nuclei were stained with DAPI
(blue). Scale bars = 20 μm.
(TIFF)
S11 Fig. Effects of TM 6 and TM 7 interference peptides on THC-induced behavioral
responses in WT and 5-HT2AR OKmice. Pretreatment with TM 6, but not with TM 7, pep-
tides (0.2 μg/ 2 μl ICV) blocked the memory deficits and anxiolytic-like behavior induced by
THC (3 and 0.3 mg/kg, respectively) in WT mice (A and B), but neither TM 6 nor TM 7 pep-
tides modified these effects in 5-HT2AR KOmice (F and G) (n = 4–6). Hypolocomotion, hypo-
thermia, and analgesia induced by THC (10 mg/kg) were not altered by pretreatment with TM
6 or TM 7 peptides in WT mice (C–E) or in 5-HT2AR KO animals (H–J) (n = 7–11). All data
represent mean + SEM.  p< 0.05,  p< 0.01,  p< 0.001 versus vehicle. The statistical
analyses used and their corresponding F and p values are shown in S2 Table.
(TIF)
S1 Table. Statistical analyses used for the behavioral data presented in Figs 1, 2, and 10.
Corresponding F and p-values are shown.
(DOCX)
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S2 Table. Statistical analyses used for the behavioral data presented in S1 Fig and S9 Fig.
Corresponding F and p-values are shown.
(DOCX)
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